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Abstract
The aging of the central nervous system and the development of incapacitating neurological diseases like Alzheimer’s disease
(AD) are generally associated with a wide range of histological and pathophysiological changes eventually leading to a
compromised cognitive status. Although the diverse triggers of the neurodegenerative processes and their interactions are still the
topic of extensive debate, the possible contribution of cerebrovascular deficiencies has been vigorously promoted in recent years.
Various forms of cerebrovascular insufficiency such as reduced blood supply to the brain or disrupted microvascular integrity in
cortical regions may occupy an initiating or intermediate position in the chain of events ending with cognitive failure. When, for
example, vasoconstriction takes over a dominating role in the cerebral vessels, the perfusion rate of the brain can considerably
decrease causing directly or through structural vascular damage a drop in cerebral glucose utilization. Consequently, cerebral
metabolism can suffer a setback leading to neuronal damage and a concomitant suboptimal cognitive capacity. The present review
focuses on the microvascular aspects of neurodegenerative processes in aging and AD with special attention to cerebral blood
flow, neural metabolic changes and the abnormalities in microvascular ultrastructure. In this context, a few of the specific triggers
leading to the prominent cerebrovascular pathology, as well as the potential neurological outcome of the compromised cerebral
microvascular system are also going to be touched upon to a certain extent, without aiming at total comprehensiveness. Finally,
a set of animal models are going to be presented that are frequently used to uncover the functional relationship between
cerebrovascular factors and the damage to neural networks. © 2001 Elsevier Science Ltd. All rights reserved.
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among mammals, some differences between species do
exist. For instance, the anterior communicating artery
is a well-known anatomical unit in humans but not in
rats, while the olfactory artery can be found in rats but
not in humans (Fig. 1) (Lee, 1995). Even more remark-
able is the incomplete circle of Willis in gerbils
(Mayevsky and Breuer, 1992). The description below
mainly focuses on the human situation with some re-
marks related to the cerebral circulation of laboratory
animal models popular in cerebrovascular research.
The brain receives its arterial blood supply via two
major routes, the internal carotid arteries and the verte-
bral arteries, the latter forming the unpaired basilar
artery at the junction of the medulla and the pons. The
carotid system is responsible for the anterior circulation
of the brain while the basilar artery provides the blood
supply to the posterior cerebral circulation. Obviously,
the anterior and posterior circuits are not independent
of each other: the two are interconnected by communi-
cating arteries that create the circle of Willis at the base
of the brain providing potential shortcuts between the
lateral as well as the anterio-posterior cerebral circula-
1. Introduction
1.1. The anatomy of the cerebral circulation
1.1.1. The macro6ascular supply to the brain
Although the theme of the current review is the age-
and dementia-related breakdown of cerebral microves-
sels, it is essential to have a clear view of the arboriza-
tion and regional distribution of the larger cerebral
blood vessels. The microvascular network of the brain
operates strongly dependent on the blood flow and
resistance of the large arteries and the smaller, terminal
arterioles.
Cerebrovascular research makes use of a range of
experimental animal models such as vessel occlusions to
unravel the contribution of an optimal cerebral circula-
tion to the physiology and metabolism of the brain.
When employing laboratory animal models (the rat and
gerbil being the most frequent ones) to tackle the
pathophysiology of human cerebrovascular diseases, it
should be emphasized that although the organization of
the cerebrovascular system is in many respects similar
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tion (Fig. 1). However, the vertebral and carotid sys-
tems supply distinct brain regions as demonstrated by
McDonald and Potter (1951) in rabbits. Under physio-
logically optimal circumstances the blood streaming
through the vertebral arteries does not mix with the
blood carried by the internal carotid arteries. This
phenomenon can be demonstrated by infusing vital
dyes in the carotid or vertebral arteries, which will
appear chiefly in the corresponding intracranial vessels.
Nevertheless, if the pressure gradient in the circle of
Willis changes due to an insufficient flow in either the
anterior or posterior circuits, blood from different
origin can be re-distributed via the collateral intercom-
munication in the circle. However, the degree of com-
pensation depends on the individual variation of vessel
diameters and the symmetry of the circle of Willis
(Dickey et al., 1996). The compensatory mechanisms
can play a role when the lumen of an intracranial artery
is narrowed due to severe atherosclerosis (Hartkamp et
al., 1999) or when the common carotid arteries or the
middle cerebral arteries of laboratory animals are ex-
perimentally occluded to create a model for cerebral
ischemia (Weinachter et al., 1990; Coyle and Heistad,
1991; Mhairi Macrae, 1992).
Arteries emanating from the posterior route, that is
from the basilar artery, predominantly furnish the
brainstem and midbrain with fresh blood whereas the
cerebral hemispheres are vascularized from both the
anterior (internal carotid origin) and posterior vessels.
The two large pairs of vessels originating from the
internal carotid arteries are the anterior and the middle
cerebral arteries, the latter carrying 80% of the blood
that reaches the cerebral hemispheres. Without present-
ing a complete and comprehensive list of target areas, it
is worth following the major routes of the larger arter-
ies. The anterior cerebral arteries send their arboriza-
tion to the frontal lobe, the preoptic and supraoptic
areas, the globus pallidus and the amygdala, while the
ramifications of the middle cerebral arteries are respon-
sible for the blood supply to the temporal and parietal
cortex, important subcortical nuclei such as the basal
nuclei and the choroid plexus in the lateral ventricles.
The posterior route reaches the occipital lobe of the
hemispheres and the diencephalon containing the sen-
sory thalamus and the vital autonomic hypothalamic
nuclei.
The major arteries enter the skull at the base of the
brain and their branches consequently advance dorsally
and spread on the surface of the cerebrum in the
subarachnoid space above the pia mater. They perfo-
rate the brain parenchyma perpendicular to the cerebral
surface without establishing anastomoses with each
other. As a narrowed continuum of the subarachnoid
space, the vessels are surrounded by the so-called Vir-
chow–Robin space, which is embraced by lep-
tomeningeal cells. The space gradually disappears as
the artery penetrates deeper in the brain tissue, only the
leptomeningeal cell layer remains to form the first, very
thin layer of the artery, the tunica adventitia. The
second and the thickest layer of the vessel wall, the
tunica media, consists of one or two layers of smooth
muscle cells which are separated from the tunica adven-
titia by elastin and collagen fibers, the lamina elastica
externa. The smooth muscle cells can regulate the flow
in the vessel by contracting or relaxing, which specifies
the most important function of arteries in controlling
blood pressure and flow. Finally, the luminal layer of
the artery is practically equivalent to the endothelial cell
layer and is often referred to as tunica intima.
1.1.2. The micro6ascular system and the blood–brain
barrier
The network of fine cerebral vessels and capillary
function in the brain inherently differs from that of
arteries. The general notion that arteries regulate blood
pressure while brain capillaries maintain the blood–
brain barrier (BBB) and sustain continuous nutrient,
electrolyte and waste product trafficking between neu-
ral tissue and blood is apparently reflected in the mi-
crovascular anatomy.
Cerebral capillaries represent the finest branches of
the vascular tree and, unlike arteries, they form anasto-
Fig. 1. The anatomy of the circle of Willis as seen in human (A) and
rat (B). Abbreviations: ACA, anterior cerebral artery; ACOA, ante-
rior communicating artery; AICA, anterior inferior cerebellar artery;
ASA, anterior spinal artery; BA, basilar artery; ICA, internal carotid
artery; MCA, middle cerebral artery; PCA, posterior cerebral artery;
PCOA, posterior communicating artery; SCA, superior cerebellar
artery; VA, vertebral artery.
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Fig. 2. The ultrastructure of cerebral capillaries observed with electron microscopy. A, an electron microscopic image of a typical cortical capillary
from the frontoparietal cortex of a Wistar–Kyoto rat. B, graphic reconstruction of the vessel. Abbreviations: a, astrocytic end feet; bm, basement
membrane; em, endothelial mitochondria; en, endothelial nucleus; ep, endothelial cytoplasm; l, capillary lumen; p, pericytes; tj, tight junction.
moses and create a three-dimensional vascular network.
The density of this mesh perforating the substance of
the brain is highly variable. As a general rule, capillary
density in the gray matter was found about three times
as much as that of the white matter but it may be more
appropriate to note that the observed differences in
density apparently correlate with the activity and nutri-
ent demand of the particular brain region. Experimen-
tal data supporting this conclusion showed a prominent
correlation between capillary length per brain volume
and local cerebral blood flow (Gjedde and Diemer,
1985) and between the number of capillaries, local
blood flow and glucose utilization in a given brain area
(Klein et al., 1986). The phenomenon that metaboli-
cally active brain regions are more heavily vascularized
than less active zones is supported by the observation
that capillary density appears to be most pronounced in
areas rich in synapses, followed by cell body popula-
tions and finally neural fiber bundles. Furthermore,
microvascular density also seems to coincide with the
main task of the given brain regions: the sensory and
association centers are usually more densely vascular-
ized than motor centers. The laminar structure of the
cerebral cortex also displays a typical layer-dependent
density pattern where lamina IV followed by lamina I
receive the densest vascularization. In addition to this
density pattern, the orientation of microvessels can also
show a laminar arrangement shown by the cortical
capillaries, which run parallel to the surface in lamina I
but form a multi-oriented network in lamina IV
(Hudetz, 1997).
The cerebral capillaries display a typical ultrastruc-
ture crucial to execute BBB function (Fig. 2). The three
cellular building blocks that participate in the forma-
tion of the capillaries are the endothelial cells, the
irregularly occurring pericytes and the astrocytic end
feet attached to the vessels’ abluminal surface. The
capillary endothelial cells form one layer around the
capillary lumen and create tight junctions (also called
zonulae occludens) where they are apposed to each
other. The tight junctions seal the space between the
meeting endothelial surfaces and are considered as the
morphological basis for the BBB gaining their full
functional integrity with the maturation of the animal
(Rubin and Staddon, 1999; Kniesel and Wolburg, 2000;
Saunders et al., 2000). Other features that take care of
the selective isolation of the brain from the blood are
the lack of endothelial fenestrations and an insignificant
transport via pinocytic vesicles. The capillary endothe-
lial cells are further characterized by a relatively high
number of mitochondria, which can provide the energy
needed for the working of the specific BBB transport
proteins (e.g. glucose- and amino acid transporters).
The endothelial cells are surrounded by a 30- to
40-nm-thick basement membrane (BM) (Fig. 3) which
is often a target of investigation due to its frequently
observed malformations under pathophysiological con-
ditions (for example Alzheimer’s disease) (Perlmutter
and Chui, 1990; Claudio, 1996; Kalaria, 1996; Farkas
et al., 2000b). The extracellular matrix components of
Fig. 3. Schematic drawing of the cerebral capillary basement mem-
brane.
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the BM, namely the intrinsic collagen type IV, heparan
sulfate proteoglycan (HSPG), laminin and the extrinsic
fibronectin are known to be produced by the cell types
of the capillaries. These BM constituents are arranged
into a trilaminar structure with an endothelial layer
(lamina rara interna), an astrocytic layer (lamina rara
externa) and a transitory, fused layer in-between the
two (lamina densa) (Fig. 3). Collagen type IV, the
major structural element of the BM is preferentially
located in the lamina densa while the proteins laminin
and HSPG are more closely associated with the two
lamina rarae, which promote cell adhesion and attach-
ment (Perlmutter and Chui, 1990). Besides the widely
cited BM elements, additional proteins that are de-
posited in the BM have also been identified. Cablin,
synthesized by the endothelial and smooth muscle cells,
is such a molecule (Charron et al., 1999), suited to
cross-link cells and matrix constituents. The BM has
been suggested to provide physical support to the mi-
crovessels, control cellular migration, filter macro-
molecules, influence endothelial function, promote cell
adhesion and protect the brain against extravasated
proteins (Perlmutter and Chui, 1990).
The second, heterogeneous cell type of cerebral capil-
laries, the pericyte is inserted in the BM and covers the
vascular wall by its extended processes. Some investiga-
tors differentiate granular and filamentous pericytes
and attribute a phagocytotic role to the granular type
(Tagami et al., 1990). The size and appearance of
pericytic profiles seen with the electron microscope is
highly variable depending on the level of slicing. When
compared to endothelial cells, the density and composi-
tion of the cytoplasm looks very similar but the peri-
cytes also contain dense bodies or lysosomes. The
pericytes are often considered as a supporting cell type
of capillaries, which can regulate capillary tone (Kelley
et al., 1987). They also participate in the immune
response as shown by their relationship with
macrophages and their ability to transform into mi-
croglia. These proposals were further substantiated by
the demonstration of the presence of macrophage
markers on the pericytic surface, their phagocytotic
activity and antigen presentation (Thomas, 1999). Fur-
thermore, the pericytes can contribute to the regulation
of vascular development by inhibiting endothelial cell
proliferation and differentiation via chemical signaling
(Shepro and Morel, 1993; Hirschi and D’Amore, 1996;
Balabanov and Dore-Duffy, 1998; Martin et al., 2000;
Rucker et al., 2000).
The cerebral microvessels are supported by astrocytic
processes, which are intimately apposed to the ablumi-
nal vascular surface. These astrocytic end feet are
thought to play a dominant role in the ontogenesis and
maintenance of the BBB (Janzer, 1993). In vitro studies
have demonstrated that the close apposition of astro-
cytes to endothelial cells is necessary for the develop-
ment of typical BBB features such as the formation of
tight junctions or the expression of BBB specific
proteins (Arthur et al., 1987; Minakawa et al., 1991;
Rauh et al., 1992; Hurwitz et al., 1993). The induction
of an endothelial BBB phenotype marker, the so-called
HT7 surface glycoprotein by an astrocyte-conditioned
medium is an adequate example for the latter (Janzer et
al., 1993). Furthermore, astrocytes were implicated in
the intracerebral regulation of vascular tone and cere-
bral blood flow indicated by the expression of sero-
tonergic and cholinergic receptors on the perivascular
end feet (Cohen et al., 1996, 1999; Luiten et al., 1996;
Elhusseiny et al., 1999) and the close apposition of
noradrenergic nerve endings to the vascular astrocytic
sheath (Cohen et al., 1997). Besides receiving neuronal
innervation, the astrocytes stand in constant biochemi-
cal interaction with the endothelial cells (Goldstein,
1988; Abbott et al., 1992) shown for example by their
substance-P immunoreactivity (Michel et al., 1986), the
presence of endothelial NOS in their cytoplasm
(Wiencken and Casagrande, 1999) and the detection of
astrocytic NO release (Janigro et al., 1996).
These examples demonstrate that although the
anatomical organization of the cerebral microvascular
domain appears to be relatively simple at first sight, the
functional implications are far more complex. The vas-
cular system of the brain is designed to perform fine
and ready adjustments of vascular tone, cerebral blood
flow, BBB penetration and immunological status de-
pending on the needs of the neural tissue and environ-
mental changes. In the next chapter, the dynamics and
physiological aspects of the cerebral blood supply stand
in focus.
1.2. The physiology of cerebral blood supply
1.2.1. Flow pattern and rheological factors
The physical pattern of cerebral blood flow (CBF)
and its pathological changes in brain microvessels have
been reviewed with reference to the general rules of
fluid dynamics extended to biologically active systems
(de la Torre and Mussivand, 1993). As previously sum-
marized (de la Torre and Mussivand, 1993), a number
of major parameters can help characterize the dynamics
of blood flow in the cerebral vessels, such as flow
velocity, microturbulent flow, viscosity of the blood,
shear stress created by the vascular wall and vascular
resistance. These factors are inseparably and dynami-
cally interrelated.
The blood flow velocity, which can be routinely
determined in larger brain arteries with the use of
Doppler sonography (Maulik, 1995) and can also be
measured in the cerebral capillary bed with the sophisti-
cated intravital microscopy (Hudetz, 1997), is not equal
at all points in the vessel lumen throughout its transver-
sal profile. A flow gradient can be characterized with a
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Fig. 4. The development of microturbulent flow in cerebral vessels.
a high haematocrit value (Harrison et al., 1981). How-
ever, claiming a direct causal relationship between an
increased haematocrit and the development of ischemic
strokes based on these data could well be an overinter-
pretation of the findings. Yet, a causal relationship
between CBF and the haematocrit was convincingly
demonstrated in patients in another study: when reduc-
ing the haematocrit, a consequent improvement in CBF
was measured (Thomas et al., 1977). Supportive animal
models experimenting with isovolemic hemodilution
also showed that reducing the haematocrit without
changing the volume of circulating blood decreased
blood viscosity and could consequently enhance cere-
bral capillary perfusion and oxygen delivery (Lin et al.,
1995; Hudetz et al., 1999). Hence, we can conclude with
certainty that a lower haematocrit caring for reduced
blood viscosity improves CBF. Other properties of
erythrocytes like the rigidity of their cell membrane or
their affinity to form aggregates can also interfere with
CBF. As shown in an experimental rat model, the
aggregation of red blood cells compromises microvas-
cular perfusion (Mchedlishvili et al., 1999). In addition,
the rigidity of the erythrocyte membranes can also
affect CBF by limiting the rate of capillary perfusion.
The inflexibility of the cell membrane can hinder the
passage of erythrocytes through capillaries therefore the
membrane fluidity of erythrocytes indirectly interferes
with CBF.
The contribution of shear stress (due to the above
described velocity gradient of flow) to altered CBF can
be accomplished through changing viscosity (Kee and
Wood, 1984) and:or having an effect on vascular au-
toregulation (Rubanyi et al., 1990). The alteration of
CBF by shear stress plays the most important role in
curved blood vessel segments, where the difference in
flow velocity between the middle axis and the wall of
the vessel is highest. The increased shear stress can
present a physical stimulus to the endothelium and may
impose slowly regenerating endothelial damage (de la
Torre and Mussivand, 1993). On the other hand, shear
stress has also been suggested to stimulate mechanore-
ceptors presumably present on endothelial cells, which
would activate inward rectifier K-channels. In turn,
NO and PGI2 (prostaglandin I2) could be released
initiating an increase of vascular diameter (Rubanyi et
al., 1990).
Changes in vascular diameter directly lead to alter-
ations in vascular resistance and CBF, two inversely
related physiological parameters. Any change in lumen
radius will affect the resistance exponentially. The vas-
cular resistance and CBF can be regulated by myo-
genic, metabolic, neuronal and biochemical means,
which processes are overviewed in the following two
sections.
decreasing flow velocity approaching from the midline
of a vessel towards the vascular wall when looking at
the cross section of the vessel. Moreover, near the
vascular wall, the blood flow is reduced to a near
standstill where the blood has a cell-free plasma layer
(Fung, 1981, 1984). The plasma layer next to the vessel
wall also serves a significant biological purpose, namely
to allow nutrient and mineral transport from the blood
to the brain parenchyma from this slow moving layer
thus supplying the brain with energy substrates.
Microturbulent flow can disturb the regular passage
of blood and can develop when the usual shape of the
vascular lumen becomes irregular, e.g. locally thickened
(fibrotic arteries, capillaries with local basement mem-
brane thickening), partially obstructed (atherosclerosis)
or compressed (Fig. 4). The flow pattern in this case
becomes disrupted and random swirls can build up
compromising the slow flow of the cell-free layer near
the vessel wall (Fung, 1984). When such abnormalities
occur in microvessels, the optimal nutrient transport
through the BBB is in jeopardy and can lead to a
suboptimal cerebral metabolism.
The third rheological factor of importance is the
viscosity of the blood. The viscosity stands in an inverse
relationship with flow velocity and CBF meaning that a
higher whole blood viscosity is associated with lower
flow values. Two major factors having influence on
viscosity and thus oxygen-carrying capacity of the
blood have been identified as the haematocrit value
(Harrison, 1989) and the membrane fluidity and aggre-
gation of erythrocytes (Schmid-Schonbein, 1983). Early
indications that an increased haematocrit could con-
tribute to a lowered CBF under neuropathological cir-
cumstances were found in clinical studies. For example,
an increased haematocrit was shown to coincide with
the occlusion of the carotid arteries and associated
transient ischemic strokes in humans. In this study, the
size of cerebral strokes could be correlated with a
decreased CBF, which was suggested to be the result of
E. Farkas, P.G.M. Luiten : Progress in Neurobiology 64 (2001) 575–611 581
1.2.2. The myogenic and neurogenic regulation of
cerebral blood flow
The brain receives probably the most constant blood
supply of all body organs maintained by a very finely
tuned regulation of CBF. Physiological fluctuations in
the cerebral perfusion pressure are normally compen-
sated by the cerebrovascular autoregulation to sustain
an optimal, uninterrupted CBF. An intact autoregula-
tion is capable of keeping the CBF independent of
perfusion pressure provided the perfusion pressure
ranges approximately between 60 and 150 mmHg
(Wagner and Traystman, 1985; Paulson et al., 1990).
Below or above the given values, the autoregulatory
mechanisms become uncoupled from perfusion pressure
and lose accurate control of CBF. The dynamic mainte-
nance of CBF is achieved by changes in vascular resis-
tance, which can be controlled by local-chemical
factors, endothelial factors, autacoids (e.g. histamine,
prostaglandins, leukotrienes) and neurotransmitters
(Wahl, 1985; Wahl and Schilling, 1993).
The basic feedback mechanisms of the autoregula-
tory loop in the brain have been classified as myogenic,
chemical:hormonal, neurogenic or endothelial depen-
dent. The myogenic component of cerebral autoregula-
tion was defined as the intrinsic capacity of vascular
smooth muscle cells to contract in response to mechan-
ical stress such as an increase in transmural pressure
(Ursino, 1991). This contractile response can be visual-
ized by manipulating the transmural pressure in arteries
that triggers vasoconstriction when increased. With the
help of isolated rat or human brain artery preparations,
an increased vascular tone and a decreased lumen di-
ameter were detected when the perfusion pressure was
gradually increased (Halpern and Osol, 1985; Wallis et
al., 1996). Moreover, increased transmural pressure
caused little change in CBF unless the perfusion pres-
sure dropped below 60 mmHg, the lower limit of the
autoregulatory capacity (Wagner and Traystman,
1985). Based on these results, one can conclude that
stretch-dependent vasoconstriction keeps CBF constant
when the perfusion pressure stays within the autoregu-
latory range. As mentioned above, the cellular compo-
nents of the myogenic autoregulation were located in
the vascular smooth muscle, which depolarizes as me-
chanical pressure increases (Harder, 1985). Such a pres-
sure-activated contraction of smooth muscle cells was
described to depend on the extracellular calcium con-
centration and to be mediated by an arachidonic acid
signal transduction pathway (Harder et al., 1997). A
metabolite of arachidonic acid (20-hydroxyeicosate-
traenoic acid, 20-HETE) in vascular smooth muscle
cells serves as a potent vasoconstrictor by inhibiting the
opening of calcium activated potassium channels or by
activating L-type calcium currents (Harder et al., 1997).
However, other endothelial substances such as endothe-
lins released as a response to stimulation of the vascular
endothelium, which is the major focus of the next
section, can also indirectly elicit vascular contraction.
The neurogenic regulation of the main cerebral arter-
ies differs from that of cerebral microvessels in that the
large vessels receive extracranial innervation while the
terminal microvascular beds of the brain lack such a
neural supply. Similar to the systemic resistance vessels,
the large arteries of the brain surface and their par-
enchymal branches receive sympathetic, parasympa-
thetic and sensory fibers. A fundamental body of
information was accumulated by tract-tracing studies
which identified the superior cervical ganglion as the
major source of sympathetic fibers (Edvinsson et al.,
1990) and the sphenopalatine, otic and internal carotid
ganglia as the principal origin of parasympathetic fibers
(Branston, 1995). The perivascular sympathetic fibers
eliciting vasoconstriction were immuno-positive to sev-
eral compounds including the classical neurotransmitter
noradrenaline and neuropeptides like neuropeptide-Y
(NPY) (Uddman and Edvinsson, 1989) while smaller
pial arteries were also reported to receive serotonergic,
vasoconstrictive input from the dorsal raphe nucleus
(Lincoln, 1995). On the other hand, the parasympa-
thetic nerves showed the presence of acetylcholine
(ACh) and vasoactive intestinal polypeptide (VIP), both
potent vasodilators besides nitric oxide (NO), which
also emerged as a significant neurogenic relaxing factor
(Suzuki and Hardebo, 1993; Branston, 1995). The sen-
sory projection fibers to cerebral arteries were shown to
arise from the trigeminal ganglion and to contain addi-
tional vasodilatory peptides such as substance-P (SP)
and calcitonin gene-related peptide (CGRP) (Uddman
and Edvinsson, 1989).
The control of vasoconstriction mediated by auto-
nomic fibers exerts a basic, global and relatively rough
modulation of CBF while the finer tuning of regional
flow rates involves several additional mechanisms de-
pending on the vascular endothelium. Biochemical sig-
nals acting on or released by the endothelial cells can
substantially modify cerebrovascular resistance. The re-
ceptors and functional involvement of local, chemical
factors (adenosine), endothelial factors (thromboxanes,
endothelin, endothelium-derived constrictor:relaxing
factors and prostacycline), autacoids (histamine,
bradykinin, eicosanoids) and hormones (angiotensin,
vasopressin) (Wahl and Schilling, 1993) were widely
investigated and discussed. Here, we present a selection
of the most important findings of this research that are
relevant to the physiology and regulation of cerebromi-
crovascular blood flow.
1.2.3. The role of endothelial factors in cerebral blood
flow regulation
The vascular endothelium plays a pivotal role in CBF
regulation because an important group of vasoactive
biochemical compounds are released by and act on the
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endothelial cells. These factors are traditionally named
as endothelium-derived relaxing factors, nitric oxide
(NO) being one of them, and endothelium-derived con-
tracting factors, like endothelins. Most of the data
concerning the regulatory function of NO and endothe-
lins were collected from arterial endothelial cells, but
the release of these factors from microvascular endothe-
lium was also shown (Yoshimoto et al., 1991; Durieu-
Trautmann et al., 1993; Lovick and Key, 1995). In
microvessels, the potential target of these factors are
the perivascular astrocytes as opposed to the smooth
muscle layer in macrovessels (Durieu-Trautmann et al.,
1993).
Vascular dilation mediated by nitric oxide (NO) is a
well-described phenomenon. NO relaxes vascular
smooth muscle and increases regional cerebral blood
flow in response to shear stress to the endothelium or
stimulation by acetylcholine, bradykinin or other bio-
chemical compounds (Arnal et al., 1999). The mechani-
cal and chemical stimuli can increase the cytosolic
calcium concentration and the association of the cal-
cium:calmodulin complex to NO synthase in the en-
dothelial cells (Fleming and Busse, 1999), which in turn
modulates NO production by increasing the gene ex-
pression and:or the activity of the endothelial NO
synthase (eNOS) (Arnal et al., 1999). The origin of NO
is, however, not restricted to the endothelium: NO
released from neuronal terminals in addition to en-
dothelial sources can also regulate vascular relaxation.
In order to visualize the effects of endothelial NO
separately from that of neuronal origin, several meth-
ods have been applied. The selective blockade of the
endothelial NO synthase (eNOS), cell culture of en-
dothelial cells (Weih et al., 1998) or the use of eNOS
knockout or mutant mice (Huang et al., 1995; Strauss
et al., 2000) all delivered valuable data in NO research.
With the help of these models, it was shown that eNOS
mediated basal vasodilatation (Huang et al., 1995) and
that endothelial NO could buffer blood pressure vari-
ability (Strauss et al., 2000). Additional pioneering
work using gene therapy to enhance vasorelaxation also
made use of eNOS by associating its gene to an aden-
ovirus vector and achieving augmented NO-mediated
vasorelaxation in isolated arteries after gene transfer
(Ooboshi et al., 1998; Tsutsui et al., 2000).
Endothelins, the very potent vasoconstrictor sub-
stances isolated from cultured endothelial cells, were
widely investigated for their role in subarachnoid hem-
orrhage (SAH) Zimmermann and Seifert, 1998). The
substances have been held responsible for the delayed
cerebral vasospasm after SAH causing considerable
damage to the vascular wall. Out of the presently
known three endothelin isoforms, ET-1 seems to be the
most potent, which probably acts primarily on the
endothelin-A receptor (ET-A) (Zimmermann and
Seifert, 1998). Although most data on the functional
implications of endothelins come from pathological
changes after SAH, endothelins can be involved in the
control of CBF under physiological circumstances. As
supporting evidence, it was demonstrated that when
cerebral perfusion pressure was increased with nore-
pinephrine, CBF did not noticeably follow the evoked
increase, but when an endothelin-B receptor (ET-B)
antagonist, bosentan was administered in combination
with norepinephrine, a remarkable rise in CBF was
recorded (Mascia et al., 1999). These findings may
indicate that ET-B stimulation plays a role in the
maintenance of a constant CBF at increasing perfusion
pressure under physiological conditions. Because the
ET-A and ET-B receptors, as well as the intracellular
second messenger of endothelin action, the mitogen-ac-
tivated protein kinase (MAPK) were identified in the
vascular smooth muscle cells (Zimmermann and Seifert,
1998; Zubkov et al., 2000), the suggested regulatory
mechanism gains significance in cerebral arteries.
1.2.4. Metabolic cerebral blood flow regulation
Besides the global regulation of cerebral blood sup-
ply via changing the diameter of larger brain arteries,
CBF is also regulated locally at the level of microves-
sels, based on the metabolic activity of the particular
brain area examined. Since the brain’s fundamental
energy source is glucose and its metabolism requires
oxygen, the coupling of cerebral glucose utilization
(CGU) and cerebral metabolic rate for oxygen
(CMRO2) with CBF has been widely investigated in
physiological conditions, as well as in neurodegenera-
tive diseases. CGU is generally considered as an indica-
tor of neuronal activity, taken that glucose is used to
maintain resting membrane potential and the restora-
tion of ion gradients after an action potential (Jueptner
and Weiller, 1995). This theory may also explain the
results of the study where a local administration of
glutamate or NMDA to the rat cerebral cortex caused
a significant rise in CMRO2 and CBF (Lu et al., 1997).
Besides consuming oxygen and metabolizing glucose,
which can regulate CBF, the firing neurons also release
K. When the extracellular K concentration is raised,
the ion acts as a vasodilator on nearby vessels and
enhances CBF. At the re-establishment of neuronal
resting potential, adenosine may also come free and
cause an increase in CBF by vasodilatation (Kuschin-
sky, 1991).
Non-invasive measurements of cerebral CMRO2 in
healthy human volunteers showed a correlation be-
tween CBF and CMRO2 (Leenders et al., 1990; Hoge et
al., 1999) but these findings by themselves may not be
sufficient evidence to prove a causal, regulatory rela-
tionship between CMRO2 and CBF. Although addi-
tional animal studies provided supporting data by
demonstrating that reducing blood oxygen concentra-
tion elevated CBF proportionally (Jones et al., 1981;
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Sato et al., 1992), the effect may not be the result of a
direct regulatory loop (e.g. the carotid chemoreceptor
reflex) because the role of chemoreceptors for blood
oxygen concentration could not be unanimously ver-
ified (Miyabe et al., 1989). Rather, the reduced oxygen
concentration of blood can accompany an increase in
CBF, both potentially being a result of increased neu-
ronal activity. Therefore the metabolic regulation of
CBF is probably mediated by other by-products of
glucose metabolism, the most important being the ele-
vated concentration of CO2 and a consequent increase
in blood pH.
CO2 effect can be measured by the CO2 reactivity
test, which provides information about the functional
state of brain vessels. In man, 1 mmHg increase in
blood pCO2 causes a 2–4% increase of CBF mediated
by a concomitant change in pH which acts directly on
cerebral vessels posing the basic mechanism of regional
CBF (rCBF) regulation. An increased [H] triggers
vasodilatation while a decreased [H] leads to vasocon-
striction. Other regulatory mechanisms can potentially
modify pH reactivity.
2. Cerebrovascular changes in normal aging
2.1. Cerebral blood flow in the aging brain
A gradual functional decline and a concomitant dis-
integrating morphology typically characterize the aging
central nervous system. The physiological neural
changes are also accompanied by a well-defined decline
in cerebrovascular parameters. A decreasing CBF,
lower metabolic rates of glucose and oxygen and a
compromised structural integrity of the cerebral vascu-
lature with special attention to microvessels are repre-
sentative degenerative features of the vascular system of
the aging brain.
Numerous clinical studies employing a range of non-
invasive cerebral scanning techniques conducted investi-
gations on blood flow velocity or CBF in healthy aging
subjects. The widely used Doppler sonography has been
designed to measure flow velocity in larger arteries, and
is applied most frequently to monitor the flow in the
large basal arteries of the brain, like the middle cerebral
artery. On the other hand, methods like PET, SPECT
and gas inhalation contrasted CT can detect regional
CBF in outlined brain regions like the temporal cortex
or basal forebrain structures.
In human aging studies, the cerebral perfusion of
healthy volunteers was examined in different age
groups ranging from 14 to 100 years old (Tachibana et
al., 1984; Iwata and Harano, 1986; Reich and Rusinek,
1989; Vriens et al., 1989; Ackerstaff et al., 1990; Kawa-
mura et al., 1993; Krejza et al., 1999; Schultz et al.,
1999). Whereas some studies divided the study popula-
tion into a young (below 60 years) and an old (above 60
years) group and compared the CBF values of the
different groups (Kawamura et al., 1993; Krejza et al.,
1999), others were aiming at the investigation of CBF
and age in a continuum. This latter approach assessed
individual CBF results and correlated them with the
age of the subjects instead of comparing age groups
(Schultz et al., 1999). The results of both statistical
methods pointed to the same direction: when young
and old groups were compared, the aged had signifi-
cantly lower CBF (Reich and Rusinek, 1989; Kawa-
mura et al., 1993) and when a correlation analysis was
performed between CBF and life time, CBF negatively
correlated to the age of the individuals (Tachibana et
al., 1984; Iwata and Harano, 1986; Vriens et al., 1989;
Krejza et al., 1999; Schultz et al., 1999).
Several brain areas, such as different cortical regions
(prefrontal, frontal, temporal, parietal, occipital and
cingulate), the basal ganglia (caudate putamen,
lentiform nucleus) and the subcortical white matter
were chosen to analyze the local perfusion rate. The
CBF of the cerebral cortex and the basal forebrain was
found consistently lower with advancing age, while
CBF in the subcortical white matter was reported to be
either decreased in the elderly (Tachibana et al., 1984)
or statistically not different from younger subjects (Re-
ich and Rusinek, 1989). However, when the experimen-
tal population was also screened for white matter
lesions, the severity of the lesions in the frontal lobe
also correlated with a lower CBF (Kawamura et al.,
1993) demonstrating a possible causal relationship be-
tween the two.
At the same time, Doppler studies focused on the
blood flow velocity in the middle-, anterior- and poste-
rior cerebral arteries. The Doppler measurements
agreed with the decline observed in regional CBF in
that an age-dependent decrease of flow velocity in the
basal cerebral arteries was detected (Vriens et al., 1989;
Krejza et al., 1999). These data show that both the
regional cerebral perfusion rate and the flow velocity in
the cerebral resistance vessels decrease in healthy, aging
humans.
The descriptive clinical data explained above were
supported by further experiments to elucidate the func-
tional mechanisms underlying the age-related CBF
changes. The hypothesis that an impaired vasodilata-
tion or enhanced vasoconstriction causes the decrease
of CBF appears most plausible. Both possibilities were
tested by infusing either the vasodilator adenosine or
the dose dependently vasoconstrictive serotonin to
young adult and aged experimental animals (Jiang et
al., 1992; Hajdu et al., 1993). The adenosine superfu-
sion to the cerebrospinal fluid elicited vasodilatation in
both age groups but the increase in vascular caliber was
considerably lower in the old animals (Jiang et al.,
1992). The application of a high dose of intravascular
E. Farkas, P.G.M. Luiten : Progress in Neurobiology 64 (2001) 575–611584
serotonin lead to an augmented vasoconstrictor re-
sponse in the aged animals, which coincided with an
additional drop in CBF (Hajdu et al., 1993). These
findings indicate that the reduced CBF in aging most
probably reflects a shift in vasoregulatory capacity to-
wards the domination of constrictor responses, maybe
due to the decline of compensatory:tonic vasodilatory
mechanisms. A fine example for a deteriorating va-
sodilatory capacity was demonstrated by electrical stim-
ulation of the nucleus basalis (Linville and Arneric,
1991; Lacombe et al., 1997). The stimulation caused an
increase in regional CBF in the parietal and frontal
cortex, as well as the nucleus caudatus and the thala-
mus in young rats but did so only in the frontal cortex
and the thalamus in old animals (Linville and Arneric,
1991). These results show that there can be an age-re-
lated impairment in the perivascular neural innervation
(thus the cerebrovascular regulatory circuit) in this case
originating in the nucleus basalis, which can be held
responsible for a lower perfusion rate in the aging
brain.
2.2. Cerebral metabolic rates in normal aging
The two characteristic parameters of cerebral
metabolism are the cerebral metabolic rate for oxygen
(CMRO2) and cerebral glucose utilization (CGU). Hu-
man studies conducted to see the correlation between
life time and CMRO2 have consistently found that
CMRO2 decreased with age though the oldest members
of these study populations did not exceed 68 years of
age (Yamaguchi et al., 1986; Marchal et al., 1992;
Takada et al., 1992).
The surveys conducted on the decline of CGU
screened healthy volunteers from 18 to 78 years old and
arrived at similar conclusions to those of the CMRO2
studies. Cerebral glucose metabolic rates gradually de-
creased with advancing age with special attention to the
neocortex, the basal ganglia and the thalamus (Kuhl et
al., 1984; Eberling et al., 1995; Petit-Taboue et al.,
1998). Similar reduction in CGU reported in rats rein-
forced the clinical findings: 27-month-old Wistar rats
showed a significant reduction of CGU in the
hippocampus (Tack et al., 1989) and in numerous
telencephalic, diencephalic and medullary nuclei (Wree
et al., 1991) when compared to 3- to 4-month-old adult
controls. In addition, an age-dependent decrease in the
level of high energy phosphate metabolites like ATP
and phosphocreatine was also detected in line with the
reduced CGU values (Hoyer, 1985; Nakayama et al.,
1996).
The parallel, synchronized decline of CMRO2, CGU
and cellular energy substrates in normal aging probably
represents a gradual shift to lower cerebral metabolic
activity in general, which may be either a trigger or
more likely, the outcome of a similarly lower CBF.
Previous experiments from our lab employing chronic
experimental cerebral hypoperfusion as a model associ-
ated the decrease in CBF with morphological malfor-
mations of cerebral capillaries (Section 4.3) (De Jong et
al., 1999; Farkas et al., 2000a). The deformation of the
microvascular wall can possibly hinder nutrient trans-
port to and consequent metabolic activity of the brain
(de la Torre, 1999). Interestingly, the aging brain also
shows a compromised microvascular anatomy, which
may interact with cerebral metabolism and brain perfu-
sion, contributing to a suboptimal cognitive perfor-
mance in the elderly. The specific age-related changes in
cerebral capillary structure are the topic of the next
section.
2.3. The micro6ascular ultrastructure in the aging brain
The declining CBF and energy metabolism of the
aging brain appear to have well-described morphologi-
cal correlates. At the level of the cerebral microvessels,
both the capillary density of distinct brain regions and
the ultrastructure of the capillary walls are prone to
age-related alterations. Although increased capillary
density attributed to tissue shrinkage in the human
neocortex was reported earlier (Meier-Rouge et al.,
1984), a number of other groups found reduced cere-
bral capillary density both in humans (Abernethy et al.,
1993) and experimental animals (Amenta et al.,
1995a,b; Sonntag et al., 1997). When examining a co-
hort of 30- to 85-year-old subjects, the density of
microvessels in the hypothalamic paraventricular nu-
cleus decreased with age (Abernethy et al., 1993) while
the comparison of adult rats to an old group also led to
the observation of the rarefaction of capillaries in corti-
cal and hippocampal regions in the old animals
(Amenta et al., 1995a,b; Sonntag et al., 1997). Such a
reduction in microvascular density could be counter-
acted with the calcium channel blocker darodipine
(Amenta et al., 1995a,b), or be correlated with the
plasma level of insulin-like growth factor (Sonntag et
al., 1997) indicating the potential involvement of cal-
cium homeostasis or circulating hormonal factors in
determining capillary density in aging (see also Section
4.3).
The microanatomical studies from our lab conducted
in aging rats depicted the structural abnormalities of
the basement membrane (BM) of cerebral microvessels
in the frontoparietal motor cortex, the entorhinal cor-
tex and the hippocampus CA1 in groups of 16-, 24-, 30-
and 32-month-old rats (De Jong et al., 1990, 1991,
1992). The assessed vascular anomalies typically in-
cluded perivascular collagen deposits, also referred to
as microvascular fibrosis (Fig. 5B,C), and basement
membrane thickening (BMT) (Fig. 5A), both starting to
appear at 20 months and becoming clearly apparent at
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the senescent age of 30 months (Fig. 6B) (De Jong et
al., 1991; Luiten et al., 1994). Similar pathological
tendencies were reported in the CA1 and CA3 segments
of aging rhesus monkeys (Keuker et al., 2000). We have
also shown that additional risk factors like chronic
hypertension can accelerate the progression of these
age-related, degenerative capillary changes, which can
develop to a considerable extent already at 60 weeks of
age in spontaneously hypertensive stroke-prone rats
(SHR-SP) (Fig. 5G–I, Fig. 6D) (Farkas et al., 2000d).
Fig. 5. Electron microscopic photographs of capillary basement membrane pathology in the frontoparietal cortex of 30-month-old Wistar rats
(panels A, B & C), in the hippocampus CA1 area of 14-month-old Wistar rats with permanent experimental cerebral hypoperfusion (2VO) (panels
D, E & F) and in the frontoparietal cortex of 60-week-old spontaneously hypertensive stroke-prone rats (SHR-SP) (panels G, H and I). A, D &
G, basement membrane thickening (BMT) corresponding in the three conditions; B, E and H, fibrosis with well discernible fiber formation in the
three conditions; C, F & I, amorphous fibrosis with similar appearance in the three conditions. Abbreviations: e, endothelial cell; l, capillary
lumen; p, pericyte; *, basement membrane. Arrowheads are pointing at the site of basement membrane pathology.
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Fig. 6. The percentage of cerebral capillaries with basement membrane deposits (BMT and:or fibrosis) in different conditions. Abbreviations:
Panel A: AD, Alzheimer’s disease; C, human non-demented control; PDd, human Parkinson’s disease with dementia. Panel C: 2VO, permanent
bilateral common carotid artery occlusion, two-vessel occlusion; SHAM, sham operated control animals. Panel D: WKY, Wistar Kyoto
normotensive rat strain; SP, spontaneously hypertensive stroke-prone rat strain. *PB0.05, **PB0.01.
The ultrastructural criteria of BMT state that the BM
shows focal thickening, which reaches a thickness at
least twice as much as a normal segment of the same
vessel (Fig. 7B). Splitting and duplication of the BM
were also assigned to this category of capillary abnor-
malities (Farkas et al., 2000c). Besides the careful defin-
ition of the electron microscopic appearance of BMT,
consensus on the nature of the amorphous material
accumulating in the BM has not been reached, yet.
Perlmutter and Chui (1990) suggested that BMT could
derive from either an increased production or a de-
creased breakdown of BM components, such as colla-
gen type IV, laminin or HSPG, which was in line with
the proposal of De Jong et al. (1990) arguing that
microvascular fibrosis and BMT were interrelated by-
products of the same degenerative process. Further-
more, additional BM proteins such as perlecan and
fibronectin were found responsible for BMT in TGF
beta-1 transgenic mice (Wyss-Coray et al., 2000). Oth-
ers identified b-amyloid accumulating either in a non-
fibrillary form or demonstrating delicate fibrils in the
capillary BM (Yamaguchi et al., 1992; Inoue et al.,
1999; Natte et al., 1999b), but such vascular b-amyloid
depositions may rather account for the more pro-
nounced BMT encountered in neurodegenerative dis-
eases (Farkas et al., 2000c) than normal aging.
Whatever the molecular constituents of BMT may be,
its functional consequences, namely hindered nutrient
and electrolyte transport mechanisms through the BBB
most probably affect cognitive or other neural
processes.
Attempts were also made to elucidate the pathophys-
iological processes that can cause the above-described
BM malformations. The L-type calcium channel
blocker nimodipine could successfully prevent the for-
mation of BM deposits in the frontoparietal cortex of
30-month-old Wistar rats after a chronic 6- or 14-
month treatment (De Jong et al., 1991). Similarly,
administration of nimodipine or nifedipine for 20 weeks
to SHR-SP rats protected against BMT in 60-week-old
animals (Farkas et al., 2000d). Based on these results, it
seems most likely that improvements in the calcium
homeostasis significantly contribute to the integrity of
the cerebral capillary BM. We suggested earlier that the
microvascular protection was probably achieved via a
calcium-related improvement in the neural regulation of
cerebrovascular function (Farkas et al., 2000d).
Not only the BM but also the vascular cell types of
cerebral capillaries can display pathological alterations
in aging. The occurrence of membranous inclusions in
the BM identified as degenerating pericytes was found
to gradually increase with age in rats (De Jong et al.,
1991; Peinado et al., 1998; Farkas et al., 2000d). The
pericytes of the aging brain were furthermore character-
ized by an increased size of pericytic mitochondria
(Hicks et al., 1983), while the mitochondrial population
itself (the total number of mitochondria) remained con-
stant (Stewart et al., 1987). Even though such clear
signs of pericytic aging were noted, pericytic aberra-
tions may not be considered as a strictly degenerative
property. Taken that the pericytes were suggested to
function as immune cells in the cerebral microvascula-
ture (Thomas, 1999), the increased number of cytoplas-
mic inclusions and enlarged mitochondria may
represent an activated, phagocytotic state of these cells.
Such an increased activity may denote a combat against
potential, age-related leakages of the BBB and, by
doing so, could effectively protect microvascular and
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neuronal integrity. Other observations also serve as
additional support for the claim that pericytic aging
should be handled separately from BM pathology. As
opposed to BM damage, which was aggravated by
hypertension, high blood pressure did not pose an
additional accelerating factor for pericytic degeneration
(Farkas et al., 2000c) and nimodipine treatment could
not prevent the development of pericytic aberrations in
aging animals either (De Jong et al., 1991). The latter
finding also suggests that the degeneration of pericytes
is probably not a calcium concentration-dependent
process.
Another prominent cell type of the cerebral mi-
crovasculature, which can be affected by the aging
process, is the endothelial cell. The common, age-re-
lated histological changes include the loss and elonga-
tion of the capillary endothelial cells, and a decrease in
the number of endothelial mitochondria, but the latter
feature was seen only in the monkey (Mooradian, 1988;
Shah and Mooradian, 1997). Although the age-depen-
dent ultrastructural changes in the microvascular en-
dothelium cannot be regarded as dramatic, the
compromised integrity of the endothelial layer can have
its moderate, functional correlates in the barrier and
carrier capacity of the BBB. As failure in the barrier
function manifests itself in transient leakage of larger
serum proteins into the brain parenchyma, BBB perme-
ability became a target of investigation. The outcome of
these studies, however, remained controversial and a
minimal, if any, BBB leakage associated with aging in
the absence of neurological diseases was concluded
(Mooradian, 1988; Shah and Mooradian, 1997).
The BBB carrier systems of the aging brain showed
more obvious functional decline (Pardridge, 1988). The
transport of glucose via the BBB was, for example,
reduced in 24-month-old rats compared to 3-month-old
controls (Mooradian et al., 1991), and neutral amino
acid uptake was also reported to decrease in 8-month-
old mice compared to a 3-month-old group (Samuels et
al., 1983). The interpretation of these data may not
necessarily point to a dysfunction of the transporter
proteins themselves, rather, an age-related, decreasing
demand of the neural tissue for nutrients or the deviat-
ing ultrastructure of the capillary BM may account for
the reduced transport.
3. Cerebrovascular pathology in Alzheimer’s disease
3.1. Cerebral blood flow in Alzheimer’s disease
The contribution of vascular factors to the etiology
of dementia, with particular attention to Alzheimer’s
disease (AD) has become a rapidly extending research
field in the last decade. Epidemiological studies empha-
sized the role of peripheral vascular abnormalities like
atherosclerosis or hypertension as risk factors aggravat-
ing the progression of cognitive decline (Skoog et al.,
1996; Skoog, 1997; Hofman et al., 1997; Breteler, 2000),
and a further link has been suggested between the
systemic and notably (cardio)vascular pathophysiology
and disturbed brain perfusion in AD (de la Torre, 1999;
Farkas et al., 2000a,b).
Fig. 7. Typical cerebral capillary wall pathology in the human and rat. A, intact capillary profile; B, basement membrane thickening (BMT); C,
perivascular fibrosis; D, pericytic degeneration.
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Table 1
Reduced regional cerebral blood flow in selected brain regions of Alzheimer’s disease patients indicated as the percentage of the corresponding
values of non-demented, age-matched controls
Brain region (% flow)Reference
Cerebral cortex ThalamusGlobal Basal ganglia White matter
Parietotemporal Frontal Cingulate Hippocampus
Parietal Temporal




88.5 89.5 82.5Montaldi et al.,
1990
80 80Eberling et al.,
1992
O’Brien et al., 92 89.5 89 94.3
1992
87.5Waldemar et 86.9 84.1 88.2 88.2 85.9
al., 1994
73.8Ohnishi et al., 72.6
1995
Ishii et al., 84.9 89.6 86.4
1997
Imran et al., Reduced Reduced Reduced
1999
79.3 88.3Ishii et al.,
1998
73.5 73 85.7 87.3Kobari et al., 85
2000
The growing literature addressing the issue of an
altered CBF in AD established unanimously a de-
creased global CBF typical of the disease (Table 1).
Even though there is a general consensus on a lower
cerebral perfusion in AD, the regional distribution and
degree of the drop in CBF still appears to be dependent
on several factors. To mention the most important
ones, the severity and particular symptoms of dementia,
the age of the patient and the onset and duration of
dementia can, for example, influence regional CBF
(rCBF). In addition, the methodological approaches
like the application of different imaging techniques
(H215O PET, 99mTc-HM-PAO SPECT) or the choice of
the reference region (occipital lobe, cerebellum, and
whole brain) may also deliver some variation in the
data. Despite the number of sources that can interfere
with rCBF readings, the parietal and temporal cortices
were consistently shown to be affected (Costa et al.,
1988; Komatani et al., 1988; Montaldi et al., 1990;
Eberling et al., 1992; O’Brien et al., 1992; Ohnishi et al.,
1995; Ishii et al., 1997; Imran et al., 1999). Reduced
rCBF in the frontal cortex in AD was also reported but
with less consistency (Montaldi et al., 1990; O’Brien et
al., 1992; Imran et al., 1999). In some cases, even
though a significant decrease in rCBF in the frontal
cortex compared to age-matched controls could not be
established, the flow rate in the AD group still corre-
lated with the assessed dementia score (Hasegawa’s
Dementia Scale, HDS) (Komatani et al., 1988). Others
showed a significant reduction in frontal rCBF when
comparing mild AD to moderate AD but not when AD
patients and controls were weighed against each other
(Eberling et al., 1992). Hence, it seems likely that
lowered rCBF in the frontal lobe becomes evident at
more advanced stages of AD.
The reported degree of rCBF reduction appeared to
be uniform among the temporal, parietal and frontal
areas, although the drop of rCBF in the frontal cortex
seemed to be slightly though not significantly less than
in the parietotemporal lobe. Regional CBF values in
the parietotemporal region of AD patients ranged ap-
proximately between 80 and 90% in comparison with
healthy volunteers (Costa et al., 1988; Komatani et al.,
1988; Montaldi et al., 1990; Eberling et al., 1992;
O’Brien et al., 1992; Ohnishi et al., 1995; Ishii et al.,
1997) while one study reported a decrease even to
71–75% in rCBF of the hippocampus and the parietal
cortex in their cohort (Ohnishi et al., 1995).
Regarding the severity of dementia, significant reduc-
tion of rCBF in the dorsolateral frontal cortex was
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measured in moderate but not in mild AD (Eberling et
al., 1992). Furthermore, correlation analysis between
the cognitive status of the patients visualized by a
variety of dementia evaluating scoring systems and the
degree of cerebral hypoperfusion repeatedly provided
evidence for the association of the two parameters
(Komatani et al., 1988; Montaldi et al., 1990; Eberling
et al., 1992; O’Brien et al., 1992; Ohnishi et al., 1995;
Imran et al., 1999). Dementia scores obtained by the
Hasegawa’s Dementia Scale (HDS) were in proportion
with rCBF in the frontal, temporo-parietal and parietal
cortices, and in the hippocampus (Fig. 8), as well as
with CBF calculated for the whole brain (Komatani et
al., 1988; Ohnishi et al., 1995). Mini Mental State
Examination (MMSE) scores, in a similar way, corre-
lated to rCBF in the (dorsolateral) frontal cortex, the
parietal cortex, and the posterior temporal lobe
(DeKosky et al., 1990; Eberling et al., 1992; O’Brien et
al., 1992; Imran et al., 1999). The results of the CAM-
COG (Cambridge Cognitive Examination) test, a simi-
lar but more extensive equivalent of MMSE, were also
in a significant relationship with rCBF in the frontal,
parietal, (posterior) temporal and parieto-temporal cor-
tical areas (Montaldi et al., 1990; O’Brien et al., 1992).
Taken together, these data can provide compelling evi-
dence for a reduced rCBF in the cerebral cortex, which
is proportional to the degree of cognitive decline typical
for AD.
Alzheimer’s disease can be more securely established
as the specific diagnosis of dementia when the post
mortem analysis of the brain delivers neuropathological
confirmation. Occasionally it is discovered only in the
post mortem material that the subject diagnosed as an
AD patient had multiple cerebral infarcts and rather
belongs to the group of multi infarct dementia cases, or
conversely, dementia patients of miscellaneous origin
appear to have typical AD neuropathology. Therefore
the correlation between CBF and AD-like neural le-
sions could add supplementary aspects to the relation-
ship between CBF and AD. Unfortunately, no clinical
study performed a correlation analysis between CBF
and the severity of neuronal breakdown in AD, but
experimental models did aim at unravelling a connec-
tion between cerebral hypoperfusion and neuronal
damage. The permanent ligation of major arteries sup-
plying the brain has been developed as a model to
investigate the histological and behavioral effects of a
reduced CBF. The bilateral occlusion of the common
carotid arteries of rats (2VO) led to a dramatic initial
drop in rCBF which returned to 30–45% of rCBF in
the cortex and 20% reduction in the hippocampus 1
week after surgery (Tsuchiya et al., 1992) while the
more severe three-vessel occlusion (3VO) ligating the
subclavian artery in addition to the common carotid
arteries caused a dramatic 25–80% drop in the parietal
Fig. 8. Correlation between regional cerebral blood flow (rCBF) and
the severity of dementia in Alzheimer’s disease. A, hippocampal
rCBF (modified from Ohnishi et al., 1995); B, frontal cortex; C,
temporo-parietal cortex (modified from Komatani et al., 1988;
reprinted by permission of the Society of Nuclear Medicine).
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cortex and a 40–60% decrease in the hippocampus at 3
or 9 weeks following the occlusion (de la Torre et al.,
1992). The histological examination of the 2VO brains
after 190 days of hypoperfusion showed a significant
loss of hippocampal CA1 neurons and a greater glial
fibrillary acidic protein (GFAP) immunoreaction, the
sign of reactive gliosis (Pappas et al., 1996). The
hippocampal cell loss was later identified to be the
result of apoptotic cell death (Bennett et al., 1998). At
the same time, the 3VO condition led to the observa-
tions that the hippocampal CA1 damage represented
necrosis of pyramidal cells accompanied also with a
higher density of GFAP immunoreactivity (de la Torre
et al., 1992). The discrepancy in the nature of neuronal
injury may stem from the degree of cerebral hypoper-
fusion created in the two paradigms (2VO or 3VO),
since apoptotic and necrotic cell death in neuronal
populations can be sequential depending on the sever-
ity of the insult. Finally, the extracellular accumulation
of amyloid precursor protein (APP) and its cleavage to
b-amyloid-like fragments in the hippocampus of aging
rats was described in the 2VO paradigm, as well (Pap-
pas et al., 1997; Bennett et al., 2000). Although all
these data were obtained by imposing a very dramatic
drop in rCBF never encountered in humans (which
basically renders the strict comparison with AD lim-
ited), these experiments are very valuable from several
points of view. First, they reinforce the coincidence of
decreased rCBF with neuronal damage. Second, these
animal models proposed a possible causal order of
cerebral hypoperfusion and the subsequent neuronal
injury. Third, the use of the experimental cerebral
hypoperfusion models amply demonstrated the sorts of
potential neurodegenerative features that may arise as
a consequence of chronically reduced CBF. In sum-
mary, the experimental findings are arguing for a link
between compromised CBF and neuronal histopathol-
ogy.
3.2. The cholinergic hypothesis of cerebral blood flow
regulation and its implications in Alzheimer’s disease
A marked deficiency in cholinergic neurotransmis-
sion is one of the distinguishing degenerative features
of AD. The loss or shrinkage of cholinergic neurons in
the basal forebrain and the medial septum and the
disappearance of cholinergic projection fibers from the
nucleus basalis (NBM) to the neocortex and from the
medial septum to the hippocampus were widely investi-
gated in view of the concomitant memory deficits typi-
cal of AD (Gaykema et al., 1992; Muir et al., 1993;
Whitehouse, 1998). Whereas studies on the substantial
contribution of the cholinergic pathways to cognitive
processes have a long history, the capacity of this
network to influence CBF has only recently gained
more attention. It has been recognized that the activa-
tion of the substantia innominata:NBM complex (SI:
NBM) could increase regional CBF by inducing
vasodilatation in cortical microvessels (Fig. 10A)
(Biesold et al., 1989; Vaucher et al., 1994, 1995; Barbe-
livien et al., 1999). The striking coincidence of a re-
duced cortical CBF and cholinergic neurodegeneration
of the NBM both seen in AD patients has stimulated
more extensive research in this field.
The involvement of acetylcholine (ACh) as a neuro-
transmitter in the control of regional CBF was demon-
strated by the administration of cholinergic drugs such
as scopolamine, physostigmine or eptastigmine. When
a group of human subjects was treated with scopo-
lamine, a non-selective muscarinic ACh receptor
blocker, a 20% decrease of CBF in the frontal cortex
was detected (Honer et al., 1988). On the other hand,
the application of the ACh-esterase inhibitors
physostigmine and eptastigmine, which increase the
extracellular level of endogenous ACh, led to a signifi-
cant increase of CBF in a wide variety of brain regions
in the rat and man (Scremin et al., 1993; Blin et al.,
1997; Peruzzi et al., 2000). Although these experiments
provided convincing evidence for the involvement of
ACh in CBF regulation, the origin and exact target
structures of the neurotransmitter still remained to be
clarified.
The source of cholinergic innervation to cortical ves-
sels was identified by either the lesion or the stimula-
tion of the cholinergic basal nuclei, and the consequent
measurement of changes in CBF (Biesold et al., 1989;
Vaucher et al., 1994, 1995, 1997a; Barbelivien et al.,
1999). These experiments can be regarded complemen-
tary to the drug treatment studies but it must be kept
in mind that although the largest cell population in the
SI:NBM complex is cholinergic, other cell types (e.g.
Fig. 9. Decrease in cerebrocortical blood flow due to unilateral
biochemical lesion of the nucleus basalis magnocellularis (NBM). The
drop in CBF in the lesioned hemisphere is given as side-to-side
difference compared to the intact, contralateral side. Abbreviations:
FRC, frontal cortex, PC, parietal cortex (modified from Peruzzi et al.,
2000; reprinted by permission of The New York Academy of Sci-
ences).
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GABAergic) also mingle with them and are represented
to a lesser extent. Thus, it should be anticipated that
the lesioned or electrically stimulated nucleus basalis
neurons might not exclusively employ ACh as their
neurotransmitter.
The unilateral lesion of the SI:NBM by ibotenic acid
injection in rats offered the possibility to compare CBF
in the lesioned side to the intact, contralateral hemi-
sphere. According to the expectations, a significant
drop in cortical CBF was detected in the ipsilateral
hemisphere 1–5 weeks after the lesion (Fig. 9) (Gomi et
al., 1991; Peruzzi et al., 1996, 2000) giving support to
the assumption that the basal forebrain can modulate
regional CBF in the neocortex. Hence, the loss of
cortical cholinergic innervation in AD may contribute
to the reported reduced CBF in the disease in a similar
fashion. Data accomplished simultaneously by other
experiments employing stimulation of the SI:NBM cor-
roborated the same line of reasoning. Electrical stimula-
tion of the SI:NBM via chronically implanted
electrodes (Vaucher et al., 1994, 1995, 1997a) or the
neurochemical activation of the SI with the cholinergic
agonist carbachol (Barbelivien et al., 1999) both re-
sulted in a significant increase of regional CBF in the
cerebral cortex and subcortical, extrapyramidal struc-
tures. The outcome of these studies thus securely estab-
lished the concept of a cholinergic neurogenic
component of CBF regulation, which originated in the
basal forebrain and predominantly affected cerebral
cortical areas. Nevertheless, the question was still left
open whether projections from the SI:NBM were direct
or indirect and whether ACh was the final neurotrans-
mitter at the perivascular sites or an intermediator at
preceding synapses.
The physiological studies described above already
tackled this problem and arrived at the conclusion that
the nature of innervation from the basal forebrain was
probably region-dependent. More specifically, the exis-
tence of a direct projection to the cortical microcircula-
tion — as opposed to subcortical structures — was
suggested based on the pattern of uncoupling between
CBF and CGU after electrical stimulation (Vaucher et
al., 1997a). In addition, the frontoparietal cortex was
pinpointed as the more specific cortical target of cholin-
ergic innervation to microvessels because scopolamine
administration preceding chemical activation of the SI
could abolish the increase of CBF in the frontoparietal
but not in other cortical areas (Barbelivien et al., 1999).
Nonetheless, the final evidence for the direct and indi-
rect pathways from the SI:NBM to cortical microves-
sels was provided by anatomical tract tracing
experiments (Vaucher and Hamel, 1995) and the
demonstration of cholinergic receptors in the microvas-
cular domain itself (Luiten et al., 1996; Elhusseiny et
al., 1999). In the frontoparietal cortex, perivascular
nerve terminals arising from the basal forebrain were
visualized with an electron microscope after injecting
Phaseolus vulgaris leucoagglutinin (PHA-L), the widely
used anterograde tracer, into the SI. These PHA-L
Fig. 10. The cholinergic innervation of cortical cerebral vessels. A, Cholinergic projection from the nucleus basalis:substantia innominata complex
to capillaries in the frontoparietal cortex of the rat. B, Cholinergic synaptic elements in close approximation to a cortical capillary. C, Electron
microscopic image of a cortical capillary with an astrocytic end foot immunopositive for muscarinic acetylcholine receptors (dark deposits).
Abbreviations: a, astrocytic end foot; ACh-ax, axon terminal employing acetylcholine as neurotransmitter; cap, capillary; e, endothelial cell; FRC,
frontoparietal cortex; l, capillary lumen; mAChR’s, muscarinic acetylcholine receptors; NBM:SI, nucleus basalis:substantia innominata complex;
p, pericyte; *, basement membrane.
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positive nerve endings were furthermore comparable
with terminals immunoreactive for choline acetyltrans-
ferase (ChAT) (Vaucher and Hamel, 1995). The mi-
crovascular postsynaptic elements of cholinergic
neurotransmission were identified as muscarinic ACh
receptors (mAChRs) by conducting receptor binding
studies on isolated rat cerebrocortical microvessels
(Grammas et al., 1983). Further research localized the
mAChR proteins exclusively on the perivascular astro-
cytic end feet (Fig. 10) (Luiten et al., 1996; Van der Zee
and Luiten, 1999) while the mRNA of several mAChR
subtypes could be detected in cultured endothelial cells
and smooth muscle cells in addition to astrocytes (El-
husseiny et al., 1999).
Putting all these findings together, the outline of a
well-defined cholinergic pathway from the basal fore-
brain to the frontoparietal cortical microvasculature
emerges, which is capable of increasing regional CBF in
the given cortical area. Projecting the picture of this
anatomical and physiological circuitry of neurogenic
CBF regulation to AD brains, the attractive theory that
cholinergic deficits in AD have pathophysiological cere-
brovascular consequences appears to be justified. The
cholinergic neurodegeneration in the basal forebrain
can therefore account for the decreased CBF at least in
the frontal lobe, but the degeneration of indirect projec-
tions from the SI:NBM to cortical microvessels via
interneurons that release NO (Vaucher et al., 1997b;
Tong and Hamel, 1999) may also contribute to the
failure of CBF control in other cortical areas, such as
the temporal lobe.
3.3. Metabolic parameters and micro6ascular function
in Alzheimer brains
The significantly reduced CBF in AD, which may be
the outcome of an impaired vascular regulation was
also linked to a depressed cerebral glucose metabolism
reflected by cerebral glucose utilization measurements
(CGU) (Hoyer et al., 1991; Fukuyama et al., 1994). The
affected areas exhibiting suboptimal metabolism coin-
cided with those displaying a marked decrease of rCBF,
namely the temporal, parietal and, to a lesser degree,
the frontal lobe (Friedland et al., 1985, 1989;
Fukuyama et al., 1994). In addition, the lower CGU
values acquired from different cortical gyri could be
related to particular memory performances: episodic
memory failure correlated with CGU in the superior
temporal gyrus, the mesial temporal cortex and the
cingulate gyrus. Short-term memory disturbance was
accompanied by lower CGU in the angular gyrus, the
supramarginal gyrus and the superior temporal gyrus,
while semantic memory was associated with glucose
metabolism in the left inferior frontal gyrus, the tem-
poro-parietal junction, the angular gyrus and the supra-
marginal gyrus (Desgranges et al., 1998).
To specify the sequence of events, which would ac-
count for the compromised glucose utilization, a num-
ber of factors can be considered, of which the
microvascular aspects stand in focus here. Circulating
glucose penetrates the brain via the BBB by active
transport, which employs a specific glucose transporter
protein (GLUT-1) localized in the capillary endothelial
membranes at a high density. Immunolabelling and
binding experiments of GLUT-1 revealed a decrease of
GLUT-1 sites in the hippocampus and the cerebral
cortex of AD patients (Kalaria and Harik, 1989; Hor-
wood and Davies, 1994; Simpson et al., 1994). Based on
these observations, the diminishing glucose transport
through the BBB due to the decreased GLUT-1 density
could perform as the limiting step of CGU rate. Such
an explanation, however, appears to be contradictory
to the proposal that the levels of glucose transporter
expression (mRNA for GLUT-1) are regulated accord-
ing to the metabolic demand and regional CGU of the
neural tissue (Vannucci et al., 1998). This theory could
mean that the neuronal damage and a concomitantly
reduced CGU in AD should precede a decreased con-
centration of GLUT-1. The conflicting opinions may
find a compromise in the results that the significantly
reduced GLUT-1 protein concentration was not accom-
panied with a proportionally lowered GLUT-1 mRNA
level in AD (Mooradian et al., 1997) which infers the
following. Firstly, the GLUT-1 mRNA concentration
does not necessarily indicate the density of the actual
transporter protein, and secondly, CGU regulating
GLUT-1 mRNA expression is then probably not the
only factor responsible for the reduction of GLUT-1
protein density in AD. The latter conclusion is strongly
underscored by further evidence for the involvement of
brain trophic factors in the control of GLUT-1 gene
expression (Boado, 1998). Thus, CGU may not simply
be a cause but also a potential result of the reduced
GLUT-1 density in the disease.
3.4. Micro6ascular ultrastructure and its implication in
blood–brain barrier function in Alzheimer’s disease
3.4.1. Micro6ascular cell types
The vascular system of the AD brain can exhibit a
variety of histopathological properties, which can have
serious physiological consequences. Atherosclerosis in
the extracranial vessels supplying the brain (Kalaria,
1996; Hofman et al., 1997; Breteler, 2000) or amyloid
angiopathy in mid-size brain arteries (Vinters, 1987;
Coria and Rubio, 1996; Opeskin, 1996) not only physi-
cally thicken the vascular wall, but also contribute to
marked blood flow disturbances by narrowing or even
blocking the vessel lumen, initiating cerebral hemor-
rhage or massively increasing the rigidity of the arterial
wall. Besides the macrovascular lesions, the malforma-
tions of the cerebral microvessels in AD have also been
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Fig. 11. Electron microscopic photographs of pericytes in the cingulate cortex of Alzheimer’s disease patients. A, a relatively spared pericytic
profile. B, a pericyte with extensive cytoplasmic inclusions in the close proximity of the nucleus. C, a degenerated pericyte. Abbreviations: e,
endothelial cell; en, endothelial nucleus; er, erythrocyte; p, pericyte; *, basement membrane. Arrowheads are pointing at the outline of pericytes.
known for a relatively long time, but the exact identifi-
cation of the nature and composition of the artifacts
embedded in the microvascular walls has still not been
completely agreed upon. In the light microscope, mi-
crovascular abnormalities in AD appeared as atrophic
thin vessels, glomerular loop formations, fragmented
vessels and twisted or tortuous vessels (Bue´e et al.,
1997). Early ultrastructural studies often mentioned an
‘irregular’ appearance or distorted abluminal surface of
the terminal arterioles and capillaries in the AD brain,
which referred to the loss of the smooth contour char-
acteristic of healthy vessels (Scheibel, 1987; Hashimura
et al., 1991; Kimura et al., 1991). The initial morpho-
logical aberrations found in AD can be summarized
briefly as follows. The smooth muscle cells (SMC)
responsible for vascular contractility were found to
show abnormal focal constrictions and a general degen-
eration (Miyakawa et al., 1988; Hashimura et al., 1991;
Kimura et al., 1991), the astrocytic end feet often
appeared swollen (Higuchi et al., 1987; Yamashita et
al., 1991) and the pericytes displayed either atrophy
(Miyakawa et al., 1988) or were encountered at a higher
frequency in capillary profiles of AD patients than
controls (Stewart et al., 1992). The endothelial cells
demonstrated atrophy, swelling or contained irregular
nuclei (Miyakawa et al., 1988; Hashimura et al., 1991).
The basement membrane (BM) of brain capillaries ex-
hibited a robust thickening and local disruption (Man-
cardi et al., 1980; Miyakawa et al., 1988; Scheibel et al.,
1989; Yamashita et al., 1991) while the perivascular
plexus often disappeared (Scheibel, 1987; Scheibel et al.,
1989).
Detailed analysis of the morphological abnormalities
provided a more precise account of the structural mi-
crovascular changes in AD. The endothelium stands in
focus for its indispensable participation in creating the
BBB, therefore the pathological alterations in the en-
dothelial structure can very well correspond with BBB
failure such as transient leakage. The AD-related de-
generation of the capillary endothelium pointed out in
the earlier studies was verified by the absence of the
otherwise obvious immunoreactivity of specific en-
dothelial cell markers (CD34 and CD31) (Kalaria and
Hedera, 1995). Furthermore, the cytoplasmic compart-
ments of the endothelial cells were quantitatively inves-
tigated, which revealed that although the absolute
number of mitochondria was not changed (Mancardi et
al., 1985; Stewart et al., 1992), the area of mitochon-
drial profiles, as well as the density of mitochondria in
the endothelial cytoplasm were significantly reduced in
AD (Stewart et al., 1992). Because the absolute mito-
chondrial counts were not deviating from normal, con-
trol values, the reduced mitochondrial density could
indicate either endothelial swelling or mitochondrial
shrinkage, both implying impaired BBB capacity. The
number of pinocytic vesicles was reported to remain
comparable to controls (Stewart et al., 1992), but later
a strong inverse correlation was established between
mitochondrial and vesicular content (Claudio, 1996),
which may represent failing BBB barrier function for
the following reasons. The increased number of
pinocytic vesicles in cerebral microvessels was regarded
as a form of BBB disruption (Hirano et al., 1994), while
the mitochondria represent the endothelial metabolic
center providing energy for the maintenance of the
BBB. When the number of mitochondria decreases
relative to the pinocytic vesicular content in the en-
dothelial cell or inversely, the pinocytic vesicles multi-
ply relative to the number of mitochondria, less energy
is available for minimizing the non-specific vesicular
‘leakage’ across the BBB represented by the pinocytic
vesicles. An additional sign of a disrupted BBB in AD
may be the compromised morphology of tight junctions
(Claudio, 1996). The number of tight junctions per
standard vessel length was also remarkably decreased
but the length of the junctions itself did not alter
(Stewart et al., 1992).
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Furthermore, the degeneration of microvascular peri-
cytes was noted in AD brains but when the ratio of
capillary profiles containing degenerative pericytes was
compared to age-matched controls, no difference be-
tween the two sample groups was seen (Fig. 11) (Farkas
et al., 2000c). Conversely, previous observations
showed that the number of pericytic processes increased
in AD brains (Stewart et al., 1992). The two sets of
data do not stand in conflict, however, because the
increase was notable in intact and not degenerating
pericytic profiles. These findings together indicate that
AD probably does not enhance the already existing,
age-related pericytic pathology, but the proliferation of
the healthy perivascular cells can still be amplified in
the disease, possibly as a compensatory mechanism,
working against BBB disruption.
3.4.2. Micro6ascular basement membrane pathology in
Alzheimer’s disease
The prominent thickening of the basement mem-
brane (BMT) considerably affected the capillaries in the
cerebral cortex of AD subjects and was consistently
reported by a number of research groups analyzing
either biopsy tissue or post mortem material (Fig. 6A,
Fig. 12) (Mancardi et al., 1980; Perlmutter and Chui,
1990; Claudio, 1996; Farkas et al., 2000c). The ad-
vancement of BMT appeared to be neurodegeneration-
rather than AD-specific, since Parkinson’s disease pa-
tients and spontaneously hypertensive stroke prone rats
also developed microvascular BMT in the cerebral cor-
tex being in many ways comparable to that found in
AD subjects (Fig. 6) (Farkas et al., 2000a,c). Further-
more, BMT was locally associated with the neu-
ropathological events in AD. The temporal gyrus with
severe AD-like neurodegeneration was shown to selec-
tively contain microvessels with BMT in contrast to
healthy microvessels in the intact cerebellum (Zarow et
al., 1997). Among the potential candidates as molecular
constituents of BMT, collagen can be mentioned first
for the following reasons. Firstly, the deposition of
collagen fibrils in the BM was noticeable in the form of
fiber bundles (microvascular fibrosis) on the electron
microscope screen (Farkas et al., 2000c), and the bio-
chemical detection of the collagen content of cerebro-
cortical microvascular fractions also showed a
significant, AD-related increase, particularly of collagen
type IV, the basic element of the healthy BM (Kalaria
and Pax, 1995).
The other molecular BM constituents such as hep-
aran sulfate proteoglycans (HSPGs) and laminin can
also be overexpressed in AD brains. For example, the
levels of the HSPG agrin were found altered in associa-
tion with microvascular damage in AD hippocampus
and prefrontal cortex (Berzin et al., 2000). Further-
more, immunocytochemical labeling detected the pres-
ence of HSPGs and laminin not only in the vascular
walls but also in senile plaques in AD samples (Snow et
al., 1988; Perlmutter et al., 1991; Jucker et al., 1996;
Fukuchi et al., 1998). The HSPG proteins accumulated
in close approximation to capillaries and were colocal-
ized with extravascular amyloid in the frontal, temporal
and parietal cortices of AD patients (Perlmutter et al.,
1990). Further examination of the different HSPGs
showed that typically agrin, less frequently glypican
and syndecans but not perlecan was widely expressed in
cerebral blood vessels, senile plaques and neurofibril-
lary tangles of AD brains (Verbeek et al., 1999). The
wide distribution of these extracellular matrix proteins
indicates that other cell types than the typical vascular
compartments can express HSPGs and laminin. In fact,
HSPGs were immunolocalized to a subset of astrocytes
and neurons (Snow et al., 1988) and reactive astrocytes
were also described to produce laminin (Jucker et al.,
1996). Hence, the potential pathological accumulation
of HSPGs and laminin in the microvascular wall could
very well originate from the perivascular astrocytes or
neuronal plexus.
Fig. 12. Electron microscopic images of capillary basement membrane deposits from the cingulate cortex in Alzheimer’s disease. A, basement
membrane thickening. B, basement membrane splitting. C, fiber deposits in the basement membrane. Abbreviations: a, astrocytic end foot; e,
endothelial cell; er, erythrocyte; p, pericyte; *, basement membrane. Arrowheads are pointing at the sites of basement membrane pathology.
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3.4.3. Beta-amyloid peptide deposits in the
cerebromicro6ascular wall
Besides the intrinsic BM components like collagen,
HSPGs and laminin, other sorts of proteins thought to
be exogenous to the microvascular wall can also be
deposited into the BM. The toxic b-amyloid peptide
(Ab), the hallmark of AD typically occurring in extra-
cellular cerebral plaques, is often encountered as amor-
phous material or fine fibrils in the capillary BM of AD
patients (Yamaguchi et al., 1992; Perlmutter, 1994;
Inoue et al., 1999; Natte et al., 1999b). Such Ab de-
posits, also designated as cerebral microangiopathy,
may alternately account for BMT, though probably not
all forms of it since BMT is known to occur in Parkin-
son’s disease and chronic hypertension, as well (Farkas
et al., 2000a,d).
Competing theories attribute the origin of Ab caus-
ing cerebral microangiopathy to either the circulating
blood, the vessel wall itself or the brain parenchyma
(Burgermeister et al., 2000). The blood-borne Ab hy-
pothesis finds support in the experimental data that the
plasma Ab concentration is markedly increased in AD
patients (Kuo et al., 1999), that experimentally infused
Ab can be traced back in the cerebral vascular walls
(Mackic et al., 1998), and that transport mechanisms
for Ab via the BBB, such as receptor mediated trans-
port or BBB leakage caused by Ab toxicity, were also
demonstrated (Pluta et al., 1996; Zlokovic, 1996; Jancso
et al., 1998; Poduslo et al., 1999; Strazielle et al., 2000).
Advocates of the vessel wall hypothesis promoting the
concept that perivascular cells can locally produce the
accumulating Ab (Kalaria et al., 1996) have also gath-
ered compelling evidence to confirm their theory. The
mRNA of the amyloid precursor protein (APP) was
detected with in situ hybridization in endothelial cells,
in SMCs and pericytes isolated from AD brains (Natte
et al., 1999a), which established the indispensable exis-
tence of APP in the vascular domain for potential Ab
production. Another research group identified the APP
protein itself in the vascular SMCs of leptomeningeal
vessels (Shoji et al., 1990) while further evidence sup-
ported the idea of a myocytic origin of Ab by showing
that SMCs of aged dogs accumulated Ab immunoreac-
tive material of endogenous origin when being kept in
cell culture (Wisniewski et al., 1995, 2000). Conflicting
results, however, argue for other mechanisms for Ab
deposition in SMCs like the ability of SMCs to readily
internalize and assemble Ab probably via receptor-me-
diated endocytosis (Urmoneit et al., 1997). Even if
SMCs are indeed able to process Ab themselves, they
can be held responsible only for cerebral amyloid an-
giopathy (CAA), that is Ab accumulation in larger
leptomeningeal or cortical vessels, and probably not for
microangiopathy. Instead, the miscellaneous group of
pericytes or the single layer of endothelial cells could
presumably participate in the microvascular processing
of Ab. Even though the pericytes were suggested to
have the ideal features to take up APP and process the
protein to Ab (Perlmutter, 1994), experimental evidence
is scarce to support this claim. The possible endothelial
origin of Ab also seems problematic since no proof
other than the expression of the APP gene in the
presence of interleukin-1 together with the detection of
APP mRNA in the endothelial cells was gathered
(Goldgaber et al., 1989; Natte et al., 1999a). Thus, the
source of Ab in the cerebral capillary BM must be
rather the result of Ab-trafficking via the BBB, either
from the plasma to the brain, or conversely from the
nervous tissue to the cerebral circulation. Furthermore,
it also seems likely that even though the cerebrovascu-
lar cell types may not produce Ab themselves, Ab is still
seriously toxic to all the endothelium, the SMCs and
the pericytes (Kalaria, 1997; Price et al., 1997; Suo et
al., 1997; Thomas et al., 1997; Verbeek et al., 1997;
Jancso et al., 1998) and can contribute to the patholog-
ical breakdown of the BBB and compromised mi-
crovascular integrity seen in AD.
4. Animal models for cerebral hypoperfusion
4.1. Cerebral blood flow after 6ascular occlusion
4.1.1. Frequently used animal models
Since it has been anticipated that there is a dynamic
interaction between hypertension, reduced CBF, cere-
bral microvascular pathology, cognitive performance
and memory capacity, experimental models were estab-
lished to investigate the causal relationship between
these factors. The laboratory animal models offer the
possibility to take the correlation analysis between
CBF, vascular parameters and cognitive performance
accomplished in human studies one step further since
correlation analysis offers only a description of the
coincidence of particular factors, but not causality per
se. Our theory presented in the Introduction contem-
plates that chronically reduced CBF can trigger the
degeneration of the capillary ultrastructure in the brain.
Creating a reduction of cerebral blood flow in labora-
tory animals can test such a presumed sequence of
events best. The ligation of the different large arteries
that supply the brain is routinely applied under experi-
mental conditions to achieve various degrees of cerebral
hypoperfusion (Fig. 13). The bilateral occlusion of the
common carotid arteries (two-vessel occlusion, 2VO) is
a well characterized method in rats and gerbils, but the
gerbil model is more suitable for ischemia research for
the following reasons. The posterior communication
between the basilar artery and the carotid artery system
is often missing in gerbils, meaning an incomplete circle
of Willis (Mayevsky and Breuer, 1992). This anatomical
peculiarity has substantial functional implications such
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Fig. 13. Experimental rat models to impose permanent cerebral
hypoperfusion. A, bilateral common carotid artery occlusion, two-
vessel occlusion (2VO). B, cerebrovascular insufficiency by occlusion
of the common carotid arteries (a) and the subclavian artery (b),
three-vessel occlusion (3VO).
The 2VO paradigm is frequently discussed in the
context of AD because of the apparent prevalence of
cerebral hypoperfusion in the disease (De Jong et al.,
1997; de la Torre, 1999; Farkas et al., 1999). Nonethe-
less, the 2VO experiments should not be literally inter-
preted as representative of a definite carotid artery
occlusion in AD patients since the carotid flow in AD
may be hampered but not totally blocked. The 2VO
model stands for the visualization of the cerebrovascu-
lar and behavioral consequences of the reduced CBF,
whatever its trigger may be. In fact, the cause of the
lowered CBF in AD is not certain but the possibilities
may very well include (cardio)vascular factors such as
hypertension and atherosclerosis — even in the carotid
sinus (Hofman et al., 1997; Skoog, 1997; Breteler,
2000), as well as Ab-induced vascular constriction
(Paris et al., 2000), or degenerating neural regulation.
4.1.2. The time course of experimental cerebral
hypoperfusion
When the cerebral blood supply through the carotid
arteries is experimentally shut off, a compensatory re-
distribution of blood in the circle of Willis and perhaps
other processes that counteract the sudden drop in CBF
can be expected. In order to estimate how long it takes
for the cerebral circulation to normalize CBF and to
see to what degree blood flow can be restored following
2VO, it is worth following the temporal dynamics of
cerebral perfusion after the surgery. The expected re-
covery of CBF can be carefully reconstructed based on
the data available in literature (Fig. 14). The earliest
research paper on the topic reported a striking 90–95%
drop in cortical rCBF at 1 or 3 h after the ligation
(Sadoshima et al., 1983), which, however, could not be
reproduced by later studies. Most follow-up studies
point to the following time course of CBF alteration
after bilateral carotid ligation (Fig. 14). The cortical
as the incapability of the basal cerebral circulation to
compensate for a reduced blood supply via either the
carotid or the basilar arterial system. Therefore 2VO in
gerbils severely affects the anterior cerebral circulation
causing acute ischemic attacks. Due to this phe-
nomenon the rat rather than the gerbil has been chosen
to reconstruct chronic cerebral hypoperfusion compara-
ble to the human situation. The 2VO surgery in rats
produces a less marked hypoperfusion compared to the
cerebrovascular insufficiency imposed by the three-ves-
sel occlusion technique (3VO), the ligation of the sub-
clavian artery combined with the occlusion of the two
common carotid arteries (de la Torre et al., 1992;
Tsuchiya et al., 1992; Ohta et al., 1997). The ligation of
the middle cerebral artery (MCAO) is also in practice
but has been more regularly applied as an ischemic
stroke model due to its acute, severe consequences
(Nagahiro et al., 1998).
Fig. 14. Reconstruction of the temporal dynamics of cerebral blood flow after bilateral carotid artery occlusion (2VO). A, hippocampus; B,
cerebral cortex.
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rCBF was 34% of the control value at 2.5 h after
surgery, increased to about 52% 2 days later, reached
roughly 64–66% at 1 week and 80% 3 months after
2VO. Although the latest cortical rCBF value obtained
3 months after the ligation was still lowered, it did not
differ significantly from the control values any more
(Tsuchiya et al., 1992, 1993; Ohta et al., 1997). The
decrease of rCBF in the hippocampus appeared to be
less dramatic than in the cortex but the degree of
hypoperfusion was still considerable. The hippocampal
perfusion rate fell to 52% of the control 2.5 h after the
2VO surgery, 70% 2 days later, a still significant 74%
after 1 week and a non-significant 75% at 3 months
survival time (Tsuchiya et al., 1992, 1993; Ohta et al.,
1997). When the hippocampal Ammon’s horn (CA
region) and the dentate gyrus were separately exam-
ined, the CA area showed a slightly lower rCBF than
the dentate gyrus (Tsuchiya et al., 1992, 1993). The
blood flow of the same regions in the above-introduced
cerebrovascular insufficiency (3VO) model exhibited the
following alterations. The rCBF in the hippocampus
CA1 section reached only 38% of the control value 3
weeks after imposing 3VO but recovered to normal
level 9 weeks after the surgery. The cortical flow suf-
fered a setback to 85% at 3 weeks but also returned to
control level at 9 weeks (de la Torre et al., 1992).
The comparison of young and aged rats in the 3VO
paradigm delivered interesting observations. While the
CBF of 1-month-old rats recovered to normal values
already at 9 weeks after the surgical intervention as
presented above, 14-month-old animals could not com-
pensate for the reduced cerebral blood supply in the
given time frame; what is more, their hippocampal and
cortical rCBF decreased even further. In particular, the
cortical hypoperfusion was striking with its very low
rates of 26% at 3 weeks and only 20% at 9 weeks
survival time while the hippocampal rCBF stagnated
from 66 to 40% (de la Torre et al., 1992). The possible
explanation may point out the loss of regulatory capac-
ity in the aging brain which can extend to delayed or
even impaired compensatory mechanisms against a
lowered cerebral perfusion pressure and blood supply.
The regulation of rCBF would normally sustain the
gradual return of rCBF to control values as seen in
young animals.
As mentioned in Section 3.1, longitudinal clinical
studies on the etiology of AD raised the issue of the
involvement of cardiovascular factors in the disease
process. Chronic hypertension in particular is a condi-
tion, which was recently associated with cerebrovascu-
lar deficiencies in AD. Hypertension could accomplish
its detrimental effects on cerebral vessels via creating
cerebral hypoperfusion, an existing condition in hyper-
tensive patients, as well as in experimental animals with
spontaneously high blood pressure (Nobili et al., 1993;
Fujishima et al., 1995; Nakane et al., 1995; Katsuta,
1997). In particular, the results obtained with sponta-
neously hypertensive rats (SHR) demonstrated that the
cortical rCBF was reduced in the SHR animals com-
pared to normotensive controls (WKY), and the cere-
bral hypoperfusion affected more extensive regions with
the advancement of age, observed in groups of 4- and
16- to 17-month-old SHR rats (Katsuta, 1997). Fur-
thermore, a long-term antihypertensive treatment of
SHR rats restored the cortical rCBF to values of nor-
motensive controls, which also showed a significant
linear correlation with the decreasing mean arterial
pressure (Fujishima et al., 1995). Though the SHR rat
strain is not strictly a cerebral hypoperfusion model, the
coincidence of chronic hypertension and the reduced
CBF in this rat strain can reinforce the idea that
peripheral vascular factors or enhanced vasoconstric-
tion contribute to the disturbance of cerebral perfusion,
which phenomenon can be extrapolated to the aging
brain and dementia cases. Finally, the intriguing resem-
blance of deteriorated cerebral microvascular morphol-
ogy and memory disturbances assessed in SHR and
2VO rats encourage this line of reasoning further
(Farkas et al., 2000a,b), and are discussed in detail
below.
4.2. Metabolic markers in experimental cerebral
hypoperfusion
In addition to the degree of cerebral hypoperfusion,
the regional cerebral glucose utilization (rCGU) in sep-
arate brain regions was also measured in 2VO animals.
The data obtained in the experiment showed that
rCGU in cortical regions followed the reduction in
rCBF 1 week after the vascular ligation but no signifi-
cant changes occurred in the hippocampus. In fact, the
cerebral cortex emerged as the most sensitive area,
which is reflected by the constantly reduced rCGU
measurements in its six separate parts measured, while
only five out of the other 18 brain regions examined
demonstrated a significant reduction in glucose utiliza-
tion. However, correlation analysis between CGU and
CBF averaged to the whole brain showed a very signifi-
cant linear relationship in both SHAM control and
2VO animals (Tsuchiya et al., 1993).
Others examined the activity of cytochrome oxidase,
the terminal enzyme of the mitochondrial electron
transport chain, which generates ATP via oxidative
phosphorylation. Quantitative histochemistry revealed
that 4 weeks after the 2VO surgery cytochrome oxidase
activity was selectively reduced in the hippocampal
CA1 area and the posterior parietal cortex (de la Torre
et al., 1997). The diminishing mitochondrial enzyme
activity probably reflected impaired ATP synthesis and
a suboptimal neuronal energy metabolism. The fact
that the changes were detected in areas deeply involved
in spatial memory processing (hippocampus CA1)
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probably accounts for the compromised spatial learning
performance of these animals tested in the Morris water
maze (de la Torre et al., 1997).
4.3. Cerebral micro6ascular damage due to
experimental cerebral hypoperfusion
The 2VO model proved to be a very suitable method
to determine the effects of a decreased CBF on the
ultrastructure of cerebral capillaries. Unlike the acute
MCAO often imposed in stroke research, where after a
short blockage of blood flow the subsequent reperfu-
sion phenomenon is also studied, the chronically ap-
plied 2VO paradigm induces a relatively mild but
permanent brain hypoperfusion. Further difference be-
tween the MCAO and 2VO is that, in contrast with
MCAO, stroke does not normally occur in normoten-
sive animals as a result of 2VO.
In one of our previous studies (De Jong et al., 1999),
the microanatomy of brain capillaries was investigated
with electron microscopy (EM) 14 months after creat-
ing cerebral hypoperfusion by 2VO. The hippocampus
was chosen as the area of interest due to its selective
neuronal and metabolic vulnerability represented by the
neuronal damage and the reduced cytochrome oxidase
activity observed here under 2VO condition (Pappas et
al., 1996; de la Torre et al., 1997). Within the
hippocampus two distinct regions, the CA1 and the
dentate gyrus were analyzed and compared with each
other. The microvascular histopathological features
that we quantified were basement membrane (BM)
deposits and pericytic degeneration. The category of
BM deposits represented a merged group of basement
membrane thickening (BMT) and microvascular fibro-
sis described in detail above (Sections 2.3 and 3.4.2),
while pericytic degeneration was defined as irregular
membranous inclusions in the pericytic cytoplasm. The
ratio of capillaries displaying either of the two types of
abnormalities (that is BM deposits or degenerating
pericytes) was calculated and expressed as the percent-
age of the total number of capillaries analyzed. Out of
the two hippocampal regions, only the CA1 exhibited a
significant increase in both capillary BM deposits and
degenerating pericytes in the 2VO animals. When the
ratio of intact capillaries was expressed, a 20% decrease
of healthy vessels was found in the CA1 region of the
2VO rats (Fig. 6C). On the other hand, no significant
changes in microvascular ultrastructure emerged in the
dentate gyrus indicating the selective vulnerability of
the CA1 microvasculature to a reduced cerebral perfu-
sion in the hippocampus.
As a technical consideration to the 2VO experiments,
it must be noted that the microvascular consequences
of 2VO are not always restricted to the brain but can
affect the eye as well (Slakter et al., 1984). The shrink-
age of the optic nerves or the extensive disruption of
the microvasculature in the eyes associated with patho-
logical retinal appearance reported in 2VO rats (Slakter
et al., 1984; Ohta et al., 1997) gains special importance
when the animals are trained in a learning paradigm
that involves visual cues. The problem can be circum-
vented by evaluating the visual aptitude of the animals
in the given learning task in order to prove that the
expected cognitive failure indeed correlates to the cere-
bral capillary damage and not to a potential retinal
impairment.
The cerebral capillary breakdown demonstrated un-
der the 2VO condition and previously in aging rats was
also encountered in spontaneously hypertensive stroke
prone rats (SHR-SP) (Farkas et al., 2000d). The func-
tional link between these three different conditions
sharing the common pattern of cerebral capillary
pathology may well be cerebral hypoperfusion although
firm and direct evidence is still lacking to support this
view. Similar to the studies with aged rats (De Jong et
al., 1990), our SHR-SP experiments also focused on the
frontoparietal cortex where BMT significantly increased
at the age of 60 weeks with 10%, microvascular fibrosis
at 40 and 60 weeks with 3 and 9%, respectively, while
the occurrence of degenerative pericytes remained the
same comparing the hypertensive animals to a nor-
motensive age-matched group. The damage to the base-
ment membrane expressed as basement membrane
deposits (BMT and:or fibrosis) is shown in Fig. 6D.
The finding that the amount of capillary wall deposits
correlated to the systolic blood pressure in the hyper-
tensive SHR-SP group (Fig. 15) supports the theory of
a causal relationship between physiological peripheral
and cerebral morphological vascular factors.
The disruption of cerebral capillary integrity could be
prevented by the chronic application of nimodipine or
nifedipine both in normotensive, aging Wistar and in
hypertensive SHR-SP rats (Fig. 16) (De Jong et al.,
1990, 1991; Farkas et al., 2000d). Nimodipine and
nifedipine are two L-type calcium channel antagonists
from the dihydropyridine family that can block exces-
sive calcium influx either at vascular smooth muscle
cells, or at neural elements when penetrating the brain
parenchyma. Dihydropyridines moderate vasoconstric-
tion and blood pressure by targeting the vascular
smooth muscle layer (Katz et al., 1985; Fleckenstein
and Fleckenstein-Grun, 1988; Alborch et al., 1995)
while in the brain they can also serve as potent neuro-
protective agents by preventing the building up of an
extreme intracellular calcium concentration in neurons
and astrocytes (Scriabine et al., 1989; Schuurman and
Traber, 1994; Disterhoft et al., 1996). The latter possi-
bility requires that the drugs penetrate the BBB, which
was shown for both nimodipine and nifedipine (Janicki
et al., 1988; Larkin et al., 1992; Uchida et al., 1997).
The beneficial effect of the two drugs on cerebral
capillaries thus promoted the concept that a dysregula-
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Fig. 15. Correlation between capillary basement membrane deposits in the frontoparietal cortex and systolic blood pressure in normotensive
(WKY) (A) and spontaneously hypertensive stroke-prone rats (SHR-SP) (B). The graphs include animals from the following age groups and
pharmacological treatment: WKY-40, 40-week-old WKY (n6); WKY-60-plac, 60-week-old WKY without treatment (n6); WKY-60-nimo,
60-week-old WKY with chronic, oral nimodipine treatment for 20 weeks (n6); WKY-60-nife, 60-week-old WKY with chronic, oral nifedipine
treatment for 20 weeks (n6); SHR-SP-40, 40-week-old SHR-SP (n6); SHR-SP-60-plac, 60-week-old SHR-SP without treatment (n8);
SHR-SP-60-nimo, 60-week-old SHR-SP with chronic, oral nimodipine treatment for 20 weeks (n6); SHR-SP-60-nife, 60-week-old SHR-SP with
chronic, oral nifedipine treatment for 20 weeks (n6).
tion of intracellular calcium concentration contributed
to the cerebral microvascular degeneration. The fact
that nimodipine did not decrease blood pressure at the
concentration used in our study — yet it successfully
preserved cerebral capillary integrity — suggested drug
action at CNS rather than peripheral vascular level
(Farkas et al., 2000d). The possible CNS compartments
where nimodipine or nifedipine could act include astro-
cytes or neurons but probably not the cerebrovascular
endothelial cells themselves, where the presence of L-
type calcium channels (the target of dihydropyridines)
is debatable (Alborch et al., 1995). Since the astrocytic
end feet are deeply involved in BBB maintenance, the
possibility emerges that the dihydropyridine com-
pounds could protect the capillaries by preserving the
astrocytic regulation of the BBB. Alternatively, neu-
ronal populations projecting to the perivascular plexus
could also serve as the target of the calcium channel
blockers.
Cerebral hypoperfusion, also seen under chronic hy-
pertensive conditions, can create a mild cerebral is-
chemia associated with an increased intracellular
calcium concentration that can impose harmful effects
on mitochondrial function. Furthermore, the elevated
calcium concentration is known to activate detrimental
metabolic cascades and is accompanied by free radical
generation (Siesjo et al., 1995). The calcium-generated
synthesis and accumulation of the easily translocating
NO and its toxic products (Beckman, 1991; Love, 1999)
can attack the integrity of the BBB: it may cause
astrocytic dysfunction (Schubert et al., 1994) and in-
Fig. 16. The vascular protection in cortical microvessels of 20 weeks
chronic treatment with the calcium channel blockers nimodipine and
nifedipine. Abbreviations: WKY, Wistar Kyoto normotensive rat
strain; SHR-SP, spontaneously hypertensive stroke-prone rat strain;
40, 40-week-old animals; 60-plac, 60-week-old animals fed by placebo
diet for 20 weeks; 60-nimo, 60-week-old animals fed by nimodipine
containing diet for 20 weeks; 60-nife, 60-week-old animals fed by
nifedipine containing diet for 20 weeks.
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creased endothelial permeability (Wei et al., 1986;
Imaizumi et al., 1996; Lagrange et al., 1999). The
microvascular pathology in SHR-SP animals presented
here can be associated with such a chain of events.
Dihydropyridine treatment can supposedly prevent the
intracellular calcium accumulation in astrocytes and:or
neurons innervating the cerebral microvascular domain,
thus moderating free radical production (Zhu et al.,
1999) and consequent cerebral capillary injury. The
improvement of the calcium homeostasis of these neu-
ral elements also controlling capillary blood flow may
also explain the improvement in brain perfusion, which
was shown to increase in SHR rats and rabbits after
nimodipine or nifedipine treatment (Tanaka et al.,
1986; Thoren et al., 1989; Ooboshi et al., 1990; Wein-
stein, 1995).
Hence, we can draw the conclusion that cerebral
capillary damage can be initiated by an imbalance in
the intracellular calcium homeostasis of astrocytes and
neurons, which reaches its effect on microvascular ul-
trastructure via the release of toxic free radicals, the
disturbance of the neurogenic regulation of CBF and
the degree of brain perfusion.
4.4. Learning capacity and neuropathology under
experimental cerebral hypoperfusion
4.4.1. Learning and memory impairment after carotid
occlusion
The testing of learning and memory capacity of 2VO
animals, and the detection of neuronal damage com-
plete the major fields of investigation on the degenera-
tive features that may arise as a consequence of cerebral
hypoperfusion. The main focus of the behavioral and
histological experiments has been on the hippocampus
and the cerebral cortex for their selective vulnerability
shown by CBF measurements and metabolic activity
assessed in the 2VO paradigm. The learning tests most
frequently used in cerebral hypoperfusion studies had
been specially designed to unravel mainly hippocam-
pus-related spatial learning processes (Kesner et al.,
2000).
The eight-arm radial maze task (Fig. 17A) makes use
of the motivation of food-deprived animals to search
for food pellets in the maze. The rats must learn
through consecutive trials which arms of the maze are
baited and enter those arms only once. The animals
commit an error if they make revisits to the baited arms
in case not all the other pellets have been found, or if
they make non-baited arm visits when non-baited arms
are also included in the paradigm. When 2VO rats were
trained to learn the test starting either 3 days or 3
months after surgery, they committed significantly more
errors than their controls and were not able to improve
their performance to control levels even after 15 trials
(Table 2) (Ni et al., 1994; Ohta et al., 1997; Nanri et al.,
Fig. 17. The eight-arm radial maze (A) and the Morris water maze
(B).
1998). However, when the animals had mastered the
task before the onset of 2VO (pre-trained rats), and
they were placed back on the maze 3, 7 or 21 days after
the surgery as a retention test, they quickly managed to
perform like the SHAM controls. Surprisingly these
pre-trained animals demonstrated a marked setback
between 63 and 168 days after 2VO, when they made
significantly more mistakes than the controls (Ni et al.,
1994; Pappas et al., 1996; Bennett et al., 1998). The
extensive behavioral data on learning performance indi-
cated that the acquisition of spatial memory rather than
the memory retention phase was disturbed shortly after
2VO in the eight-arm radial maze, and that the long-
term effect of cerebral hypoperfusion severely impaired
retention from approximately 2 months following the
onset of 2VO.
The Morris water maze spatial learning paradigm
(Fig. 17B) also tests spatial memory acquisition and
retention, but exploits another sort of motivation,
namely the urge to escape from an unpleasant situation.
Solving the maze involves considerably more stress for
the animals than the eight-arm radial maze, possibly
enhancing group differences further (Pappas et al.,
1997). The Morris water maze protocols also vary
between research groups but the basic concept of the
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test remains the same: the acquisition period includes a
set of trials when the rats must learn the location of a
hidden platform submerged under the water surface in
a circular swimming pool. The escape latency or the
distance covered from introducing the rat into the
water till finding the platform is measured at each trial
to visualize learning performance. During the retention
trial (also called probe trial) successive to the training
sessions the platform is removed from the pool, and the
time the animals spend in the area previously contain-
ing the platform is taken as indicative of retention
capacity. The acquisition of the task in the Morris
water maze showed significant impairment at different
time points ranging from 2 weeks to 12 months after
the carotid occlusion (Fig. 18A, Table 2) (Pappas et al.,
1996; Ohta et al., 1997; De Jong et al., 1999). The
probe trial executed at 2 weeks or 3 months after 2VO
invariably confirmed compromised spatial orientation
skills (Ohta et al., 1997). Hence, the results collected in
the Morris water maze paradigm also revealed that
cerebral hypoperfusion markedly compromised spatial
learning and memory retention.
4.4.2. Cerebral histopathology in experimental cerebral
hypoperfusion
Parallel with the memory deficits, the neuronal in-
tegrity under the 2VO condition also degenerated. His-
tological examination of brain slices revealed white
matter rarefaction (Ohta et al., 1997; Nanri et al., 1998)
and a progressive neuronal damage in the hippocampus
and the cerebral cortex (Tsuchiya et al., 1992; Ni et al.,
1994; Pappas et al., 1996, 1997; Ohta et al., 1997;
Bennett et al., 1998; Nanri et al., 1998). More specifi-
cally, the hippocampus CA1 area displayed neuronal
shrinkage (Ni et al., 1994; Nanri et al., 1998), biochem-
ical and morphological signs of apoptotic cell death
such as DNA strand breaks, chromatin condensation
and cytoplasmic shrinkage (Pappas et al., 1997; Bennett
et al., 1998), pyramidal cells loss (Ni et al., 1994;
Pappas et al., 1996; Ohta et al., 1997; Bennett et al.,
1998) and a decreased immunoreactivity for micro-
tubule-associated protein 2 (MAP2), a marker protein
of neuronal dendrites (Nanri et al., 1998). Reactive
gliosis accompanying the neuronal damage in the
hippocampal CA1 segment was also enhanced
(Tsuchiya et al., 1992; Ohta et al., 1997), also shown by
the significant increase in glial fibrillary acidic protein
(GFAP) immunoreactivity (Pappas et al., 1996; Nanri
et al., 1998). The listed abnormalities also characterized
— although to a lesser degree — the neurodegenerative
processes in the cerebral cortex (Tsuchiya et al., 1992;
Ni et al., 1994; Nanri et al., 1998). In addition to the
marked neurodegeneration as a consequence of cerebral
hypoperfusion, recent investigation disclosed extracellu-
lar deposits of the amyloid precursor protein (APP)
(Pappas et al., 1997), and a progressive accumulation of
Ab peptides in aging 2VO rats detected by Western blot
analysis (Bennett et al., 2000).
4.4.3. Correlation between learning skills and
neuronal:6ascular pathology in the cerebral
hypoperfusion model
Correlation analysis between the memory data and
the histopathological changes following chronic cere-
bral hypoperfusion highlighted the hippocampal CA1
area as the central site where neuronal damage coin-
cided with impaired learning capacity. This is in agree-
ment with the well-established notion that the
hippocampus CA1 is the specific structure where spatial
Table 2
Learning impairment after permanent common carotid artery occlusion (2VO) in the rat
Age of animals at the 2VO results compared to SHAMReference Type of Time between 2VO and the start of
behavioral testonset of 2VO controlsbehavioral testing
7 weeks–9 months Eight-arm radial 3 days–4 months More errors, impaired learningNi et al., 1994
maze
Longer escape latencies, impairedPappas et al., Morris water9–10 months 14, 28, 70, 112 and 161 days
1996 maze learning
Eight-arm radial 7, 21, 63, 105 and 154 days More unbaited arm entries, impaired
maze learning
Morris waterOhta et al., 9 weeks Longer escape latencies:severe learning2 weeks:3 months
maze1997 impairment
Eight-arm radial More errors, impaired learning3 months
maze
1 month:2 months:1 year Longer escape latencies, impairedDe Jong et al., 3 months Morris water
1999 learningmaze
19 monthsde la Torre et 1, 2 and 3 weeks Longer escape latencies, impairedMorris water
learningmazeal., 1997
14 months Morris waterde la Torre et 2, 4 and 6 weeks No significant difference
mazeal., 1997
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Fig. 18. Morris water maze performance following 12 months experimental cerebral hypoperfusion (2VO). A, traveled distance in the training
trials before reaching the hidden platform. B, correlation between Morris maze performance and capillary wall pathology in the hippocampus CA1
region. C, correlation between Morris maze performance and capillary wall pathology in the dentate gyrus of the hippocampus.
learning takes place (Van der Zee et al., 1992; Shapiro
and Eichenbaum, 1999; Kesner et al., 2000). The in-
creasing number of apoptotic cells and GFAP im-
munoreactivity in the CA1 segment was significantly
related to the eight-arm radial maze performance of the
2VO animals (Pappas et al., 1996; Bennett et al., 1998).
Furthermore, the data obtained in the Morris water
maze indicated a marked relationship between spatial
learning and hippocampal microvascular breakdown
also selectively in the CA1 region but not in the dentate
gyrus. The BM deposits significantly correlated with
impaired memory in the hippocampus CA1 (Fig.
18B,C). The coincidence of neuronal damage and mi-
crovascular breakdown in the hippocampus CA1, ac-
companied by compromised spatial learning skills
suggests that these three read-outs of cognitive status
and cellular integrity are functionally related in the
chronic 2VO model, where the onset of cerebral hypop-
erfusion acts as the trigger for microvascular pathology,
neuronal damage and impaired learning. These degen-
erative changes, which develop as the consequence of
cerebral hypoperfusion, also find correlates in human
dementia such as cerebral capillary breakdown, com-
promised neuronal integrity and failing cognition. Al-
though the neuropathology of AD is a lot more
complex, cerebral hypoperfusion probably augments
the advancement of the aspects of dementia as shown
by the 2VO model.
5. Conclusions
Cerebral microvascular pathology in aging and to a
markedly pronounced degree in AD include the physio-
logical changes in cerebral perfusion — particularly the
decrease of regional cerebral blood flow in cortical
areas, a reduction of cerebral glucose utilization, the
loss of vascular innervation with special focus to the
cholinergic breakdown typical of AD and the ultra-
structural damage to capillaries in the cerebral cortex
represented by extensive basement membrane pathol-
ogy. The coincidence of these changes contributes to an
improper blood–brain barrier function in an additive
manner. A wide range of comprehensive laboratory
animal experiments attempted to unravel a causal inter-
action between these pathological vascular changes.
Fig. 19, a scheme produced by integrating the data
from our lab and those of others, shows a hypothetical
chain of events rooted in vascular deficiency, which can
augment compromised memory capacity.
Variable conditions, which extend from chronic hy-
pertension through the breakdown of neurogenic cere-
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brovascular regulation to the effect of circulating toxic
molecules such as the b-amyloid peptide, can initiate
general vasoconstriction. As such a vasoconstrictive
reaction obviously affects the resistance vessels supply-
ing the cerebral circulation, the cerebral perfusion rate
(CBF) gradually decreases causing insufficient flow in
the cerebral microvascular network. As a next step, the
reduced regional CBF can give rise to well-defined
microanatomical aberrations in the capillary ultrastruc-
ture of cortical areas (BMT, perivascular collagen de-
posits). Consequently, capillary basement membrane
pathology will either physically hinder passive nutrient
and electrolyte trafficking from blood to brain or inter-
fere with active transport processes by possibly deform-
ing the biochemical structure of transporter proteins.
The neural compartments will be thus deprived of
essential nutrients with a major focus on glucose, thus
compromising their energy status and metabolic activ-
ity. A decline in mitochondrial cytochrome oxidase
activity and ATP production detected in experimentally
hypoperfused rats are persuasive signs of such neuronal
metabolic crisis. If the condition persists for long, the
neurons exhaust their capacity to sustain the function
of carrier proteins responsible for setting the homeo-
static intracellular ion balance, respond with delay to
extracellular stimuli, and the neural circuits lose plastic-
ity. In the end, inevitable structural neuronal disintegra-
tion, even cell death may follow. The outcome of the
process can be detected at the behavioral level as cogni-
tive failure and memory dysfunction.
The connected pathological changes are obviously
interrelated, implying that the sketched circle of events
is under no circumstances a one-way route, but a more
complex network ushered by potent feed-back mecha-
nisms. Nevertheless, the theory presented here can be
regarded as the backbone of the pathological cere-
brovascular incidents associated with aging and AD,
which connects to suboptimal cognitive capacity. The
Fig. 19. Summary of the causal relationship between cerebral vascular pathological changes.
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breakdown of the cerebral circulation and the condition
of cerebral microvessels thus seem to enhance the char-
acteristic memory deficits that typify dementias like
AD.
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